Tumor inhibition or tumor promotion? The duplicity of CXCR3 in cancer

Tumor tissue includes cancer cells and normal stromal cells such as vascular endothelial cells, connective tissue cells (cancer associated fibroblast, mesenchymal stem cell), and immune cells (tumor‐infiltrating lymphocytes or TIL, dendritic cells, eosinophils, basophils, mast cells, tumor‐associate...

Celý popis

Uložené v:

Podrobná bibliografia
Vydané v:	Journal of leukocyte biology Ročník 108; číslo 2; s. 673 - 685
Hlavní autori:	Russo, Eleonora, Santoni, Angela, Bernardini, Giovanni
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States Oxford University Press 01.08.2020
Predmet:	Animals anti‐tumor immunity Biomarkers Cancer cancer immunotherapy CD8 antigen Cell activation Cell survival Cell Transformation, Neoplastic - genetics Cell Transformation, Neoplastic - metabolism Chemokines Connective tissues CXCL10 CXCL10 protein CXCL11 protein CXCR3 protein Dendritic cells Disease Susceptibility Endothelial cells Eosinophils Gene Duplication Gene Expression Regulation, Neoplastic Homeostasis Humans Immune response immune suppression Immune system Immunomodulation Immunotherapy Inflammation Leukocytes (basophilic) Leukocytes (eosinophilic) Ligands lymphocyte migration Lymphocytes Lymphocytes T Macrophages Mast cells Mesenchymal stem cells Metastases Molecular modelling Natural killer cells Neoplasms - etiology Neoplasms - metabolism Neoplasms - pathology Protein Binding Receptors, CXCR3 - genetics Receptors, CXCR3 - metabolism Signal Transduction Solid tumors Stem cells Stromal cells Tumors CXCL10 anti-tumor immunity chemokines immune suppression cancer immunotherapy lymphocyte migration
ISSN:	0741-5400, 1938-3673, 1938-3673
On-line prístup:	Získať plný text
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!

Abstract	Tumor tissue includes cancer cells and normal stromal cells such as vascular endothelial cells, connective tissue cells (cancer associated fibroblast, mesenchymal stem cell), and immune cells (tumor‐infiltrating lymphocytes or TIL, dendritic cells, eosinophils, basophils, mast cells, tumor‐associated macrophages or TAM, myeloid‐derived suppressor cells or MDSC). Anti‐tumor activity is mainly mediated by infiltration of NK cells, Th1 and CD8+ T cells, and correlates with expression of NK cell and T cell attracting chemokines. Nevertheless, cancer cells hijack tissue homeostasis through secretion of cytokines and chemokines that mediate not only the induction of an inflamed status that supports cancer cell survival and growth, but also the recruitment and/or activation of immune suppressive cells. CXCL9, CXCL10, and CXCL11 are known for their tumor‐inhibiting properties, but their overexpression in several hematologic and solid tumors correlates with disease severity, suggesting a role in tumor promotion. The dichotomous nature of CXCR3 ligands activity mainly depends on several molecular mechanisms induced by cancer cells themselves able to divert immune responses and to alter the whole local environment. A deep understanding of the nature of such phenomenon may provide a rationale to build up a CXCR3/ligand axis targeting strategy. In this review, we will discuss the role of CXCR3 in cancer progression and in regulation of anti‐tumor immune response and immunotherapy. Review on how CXCR3 ligands can shape anti‐tumor immune responses and tumor growth and of the promising possibility to target these molecules for cancer immunotherapy.
AbstractList	Tumor tissue includes cancer cells and normal stromal cells such as vascular endothelial cells, connective tissue cells (cancer associated fibroblast, mesenchymal stem cell), and immune cells (tumor-infiltrating lymphocytes or TIL, dendritic cells, eosinophils, basophils, mast cells, tumor-associated macrophages or TAM, myeloid-derived suppressor cells or MDSC). Anti-tumor activity is mainly mediated by infiltration of NK cells, Th1 and CD8+ T cells, and correlates with expression of NK cell and T cell attracting chemokines. Nevertheless, cancer cells hijack tissue homeostasis through secretion of cytokines and chemokines that mediate not only the induction of an inflamed status that supports cancer cell survival and growth, but also the recruitment and/or activation of immune suppressive cells. CXCL9, CXCL10, and CXCL11 are known for their tumor-inhibiting properties, but their overexpression in several hematologic and solid tumors correlates with disease severity, suggesting a role in tumor promotion. The dichotomous nature of CXCR3 ligands activity mainly depends on several molecular mechanisms induced by cancer cells themselves able to divert immune responses and to alter the whole local environment. A deep understanding of the nature of such phenomenon may provide a rationale to build up a CXCR3/ligand axis targeting strategy. In this review, we will discuss the role of CXCR3 in cancer progression and in regulation of anti-tumor immune response and immunotherapy.Tumor tissue includes cancer cells and normal stromal cells such as vascular endothelial cells, connective tissue cells (cancer associated fibroblast, mesenchymal stem cell), and immune cells (tumor-infiltrating lymphocytes or TIL, dendritic cells, eosinophils, basophils, mast cells, tumor-associated macrophages or TAM, myeloid-derived suppressor cells or MDSC). Anti-tumor activity is mainly mediated by infiltration of NK cells, Th1 and CD8+ T cells, and correlates with expression of NK cell and T cell attracting chemokines. Nevertheless, cancer cells hijack tissue homeostasis through secretion of cytokines and chemokines that mediate not only the induction of an inflamed status that supports cancer cell survival and growth, but also the recruitment and/or activation of immune suppressive cells. CXCL9, CXCL10, and CXCL11 are known for their tumor-inhibiting properties, but their overexpression in several hematologic and solid tumors correlates with disease severity, suggesting a role in tumor promotion. The dichotomous nature of CXCR3 ligands activity mainly depends on several molecular mechanisms induced by cancer cells themselves able to divert immune responses and to alter the whole local environment. A deep understanding of the nature of such phenomenon may provide a rationale to build up a CXCR3/ligand axis targeting strategy. In this review, we will discuss the role of CXCR3 in cancer progression and in regulation of anti-tumor immune response and immunotherapy. Tumor tissue includes cancer cells and normal stromal cells such as vascular endothelial cells, connective tissue cells (cancer associated fibroblast, mesenchymal stem cell), and immune cells (tumor‐infiltrating lymphocytes or TIL, dendritic cells, eosinophils, basophils, mast cells, tumor‐associated macrophages or TAM, myeloid‐derived suppressor cells or MDSC). Anti‐tumor activity is mainly mediated by infiltration of NK cells, Th1 and CD8+ T cells, and correlates with expression of NK cell and T cell attracting chemokines. Nevertheless, cancer cells hijack tissue homeostasis through secretion of cytokines and chemokines that mediate not only the induction of an inflamed status that supports cancer cell survival and growth, but also the recruitment and/or activation of immune suppressive cells. CXCL9, CXCL10, and CXCL11 are known for their tumor‐inhibiting properties, but their overexpression in several hematologic and solid tumors correlates with disease severity, suggesting a role in tumor promotion. The dichotomous nature of CXCR3 ligands activity mainly depends on several molecular mechanisms induced by cancer cells themselves able to divert immune responses and to alter the whole local environment. A deep understanding of the nature of such phenomenon may provide a rationale to build up a CXCR3/ligand axis targeting strategy. In this review, we will discuss the role of CXCR3 in cancer progression and in regulation of anti‐tumor immune response and immunotherapy. Tumor tissue includes cancer cells and normal stromal cells such as vascular endothelial cells, connective tissue cells (cancer associated fibroblast, mesenchymal stem cell), and immune cells (tumor-infiltrating lymphocytes or TIL, dendritic cells, eosinophils, basophils, mast cells, tumor-associated macrophages or TAM, myeloid-derived suppressor cells or MDSC). Anti-tumor activity is mainly mediated by infiltration of NK cells, Th1 and CD8 T cells, and correlates with expression of NK cell and T cell attracting chemokines. Nevertheless, cancer cells hijack tissue homeostasis through secretion of cytokines and chemokines that mediate not only the induction of an inflamed status that supports cancer cell survival and growth, but also the recruitment and/or activation of immune suppressive cells. CXCL9, CXCL10, and CXCL11 are known for their tumor-inhibiting properties, but their overexpression in several hematologic and solid tumors correlates with disease severity, suggesting a role in tumor promotion. The dichotomous nature of CXCR3 ligands activity mainly depends on several molecular mechanisms induced by cancer cells themselves able to divert immune responses and to alter the whole local environment. A deep understanding of the nature of such phenomenon may provide a rationale to build up a CXCR3/ligand axis targeting strategy. In this review, we will discuss the role of CXCR3 in cancer progression and in regulation of anti-tumor immune response and immunotherapy. Tumor tissue includes cancer cells and normal stromal cells such as vascular endothelial cells, connective tissue cells (cancer associated fibroblast, mesenchymal stem cell), and immune cells (tumor‐infiltrating lymphocytes or TIL, dendritic cells, eosinophils, basophils, mast cells, tumor‐associated macrophages or TAM, myeloid‐derived suppressor cells or MDSC). Anti‐tumor activity is mainly mediated by infiltration of NK cells, Th1 and CD8+ T cells, and correlates with expression of NK cell and T cell attracting chemokines. Nevertheless, cancer cells hijack tissue homeostasis through secretion of cytokines and chemokines that mediate not only the induction of an inflamed status that supports cancer cell survival and growth, but also the recruitment and/or activation of immune suppressive cells. CXCL9, CXCL10, and CXCL11 are known for their tumor‐inhibiting properties, but their overexpression in several hematologic and solid tumors correlates with disease severity, suggesting a role in tumor promotion. The dichotomous nature of CXCR3 ligands activity mainly depends on several molecular mechanisms induced by cancer cells themselves able to divert immune responses and to alter the whole local environment. A deep understanding of the nature of such phenomenon may provide a rationale to build up a CXCR3/ligand axis targeting strategy. In this review, we will discuss the role of CXCR3 in cancer progression and in regulation of anti‐tumor immune response and immunotherapy. Review on how CXCR3 ligands can shape anti‐tumor immune responses and tumor growth and of the promising possibility to target these molecules for cancer immunotherapy.
Author	Santoni, Angela Russo, Eleonora Bernardini, Giovanni
Author_xml	– sequence: 1 givenname: Eleonora surname: Russo fullname: Russo, Eleonora organization: Laboratory affiliated to Institute Pasteur—Italia – sequence: 2 givenname: Angela surname: Santoni fullname: Santoni, Angela organization: IRCCS, Neuromed – sequence: 3 givenname: Giovanni orcidid: 0000-0002-3705-2598 surname: Bernardini fullname: Bernardini, Giovanni email: giovanni.bernardini@uniroma1.it organization: Laboratory affiliated to Institute Pasteur—Italia
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/32745326$$D View this record in MEDLINE/PubMed
BookMark	eNqFkTFv2zAQhYkiQeMk3TsVArp0UXrHIyl6KhojSVs4CGB46EZQNIUwkESXklD435dqnCVDO5F8-N7x8N45O-lj7xl7j3CFAPzzj_X1lbzfAHEoOcjNG7bAJemSVEUnbAGVwFIKgDN2PgxPABlU8JadEa-EzPcFu9lOXUxF6B9DHcYQ-yK_xr_aPsUuztKXYvvoi920b4ML46GITbH6udpQdhXO9s6nS3ba2Hbw747nBdve3mxX38r1w9331dd16YQAWTbYqB2XVNeS81pKUg416ga5dc5qgYiV4oRCg9AOba1Icy-qXcM5EdIF-_Q8Nq_2a_LDaLowON-2tvdxGgwXBFQJUsuMfnyFPsUp9Xk5Q1zoaolKU6Y-HKmp7vzO7FPobDqYl3wyoJ4Bl-IwJN-YnICdQxmTDa1BMHMRJhdhjkWYuYhshFfGl9n_sBz_-h1af_gvPwsIKqf4B-22lt0
CitedBy_id	crossref_primary_10_1007_s12094_023_03126_4 crossref_primary_10_3390_ijms232113277 crossref_primary_10_1038_s41467_024_52555_4 crossref_primary_10_3390_cancers13092248 crossref_primary_10_1038_s41420_023_01312_5 crossref_primary_10_3390_biomedicines10112940 crossref_primary_10_2147_IJN_S479741 crossref_primary_10_1016_j_ccell_2023_11_011 crossref_primary_10_1136_jitc_2023_007035 crossref_primary_10_1096_fj_202301764RR crossref_primary_10_1016_j_cellimm_2023_104663 crossref_primary_10_1371_journal_pone_0306525 crossref_primary_10_1016_j_tranon_2025_102413 crossref_primary_10_1186_s12885_022_09926_1 crossref_primary_10_1186_s12885_022_10451_4 crossref_primary_10_1172_JCI184036 crossref_primary_10_1007_s40272_024_00653_7 crossref_primary_10_3390_ijms241915009 crossref_primary_10_1016_j_nantod_2023_102129 crossref_primary_10_1097_CAD_0000000000001543 crossref_primary_10_3390_cancers13236132 crossref_primary_10_1016_j_jpha_2023_11_012 crossref_primary_10_3390_cancers15174379 crossref_primary_10_3389_fonc_2022_975644 crossref_primary_10_1080_14728222_2024_2433130
Cites_doi	10.1186/bcr3115 10.1056/NEJMoa020177 10.1016/S0065-230X(10)06003-3 10.1186/1476-4598-11-3 10.1016/j.humpath.2015.08.004 10.1073/pnas.0912852107 10.1080/10428194.2017.1295144 10.1186/1471-2490-14-12 10.4049/jimmunol.1502376 10.1038/ncomms8458 10.1007/s00262-010-0876-3 10.1158/0008-5472.CAN-06-3087 10.1038/nri3049 10.1038/nrc2499 10.1016/j.canlet.2011.03.025 10.1016/j.ctrv.2017.11.007 10.1097/CJI.0b013e318031b551 10.1016/S0021-9258(18)53303-2 10.1097/01.ju.0000127726.25609.87 10.1093/jnci/djv199 10.4149/neo_2016_017 10.1007/s10555-010-9256-x 10.4049/jimmunol.1101293 10.1128/JVI.02007-13 10.18632/oncotarget.7468 10.1002/path.4258 10.1186/s12885-018-4384-8 10.1158/0008-5472.CAN-08-2281 10.1038/nm1093 10.1038/nature10169 10.1046/j.1365-3083.2001.00984.x 10.1016/j.juro.2014.01.100 10.1002/ijc.25236 10.1038/nature10166 10.1016/j.it.2012.05.007 10.1080/2162402X.2016.1218105 10.1371/journal.pone.0128662 10.1158/0008-5472.CAN-10-3277 10.1074/jbc.M106912200 10.13055/ojhmt_3_S1_03.120221 10.4049/jimmunol.176.4.2581 10.1016/j.yexcr.2018.08.006 10.1073/pnas.1118104109 10.18632/oncotarget.2519 10.1111/bph.12064 10.1172/JCI71951 10.1038/labinvest.3700453 10.1002/cncr.20747 10.1002/ijc.20823 10.3892/ol.2011.300 10.1158/1078-0432.CCR-19-2803 10.1084/jem.184.3.963 10.1038/ncomms1239 10.4049/jimmunol.0902575 10.1677/ERC-10-0107 10.1158/0008-5472.CAN-06-0709 10.1158/1535-7163.MCT-08-0485 10.1158/0008-5472.CAN-12-1187 10.18632/oncotarget.7360 10.1007/s00262-014-1629-5 10.1016/j.canlet.2003.10.036 10.1038/nrc3245 10.1016/j.canlet.2019.02.016 10.1016/j.bbrc.2013.08.072 10.4049/jimmunol.1202390 10.1182/blood.V95.2.627 10.3389/fmed.2018.00271 10.4049/jimmunol.1201906 10.1158/0008-5472.CAN-12-0579 10.1016/j.ejca.2006.01.006 10.1016/j.jcmgh.2018.08.008 10.1002/path.1745 10.1182/blood-2007-09-110312 10.1074/jbc.M110.170324 10.3390/ijms20112674 10.1007/s00262-006-0133-y 10.1016/j.biocel.2008.01.008 10.1097/CJI.0b013e31802e089a 10.1080/2162402X.2016.1250051 10.1053/j.gastro.2009.10.057 10.3389/fimmu.2017.01970 10.1080/2162402X.2015.1074374 10.1074/jbc.272.23.14899 10.1016/j.imlet.2003.10.020 10.1182/blood-2008-12-196618 10.1016/j.ctrv.2018.10.005 10.1158/2159-8290.CD-18-1020 10.1007/s00277-003-0679-0 10.1007/s12253-015-9947-2 10.1016/j.ccell.2019.05.004 10.1182/blood-2006-10-049072 10.1172/JCI127125 10.1038/sj.bjc.6605078 10.1038/onc.2011.633 10.1158/0008-5472.CAN-08-1440 10.1189/jlb.0910506 10.1038/nature15520 10.1158/1078-0432.CCR-11-3314 10.1038/sj.bjc.6606056 10.1124/mol.116.105502 10.1016/j.biopha.2011.12.003 10.1016/j.ebiom.2019.08.067 10.1084/jem.20061890 10.4049/jimmunol.179.6.4272 10.3389/fimmu.2013.00012 10.1371/journal.pone.0033747 10.3324/haematol.2015.133470 10.1111/jcmm.12890 10.1111/j.1365-2567.2010.03384.x 10.4049/jimmunol.173.10.6234 10.1002/ijc.21135 10.1038/nature14011 10.1126/science.1129139 10.1186/s40425-019-0751-5 10.4049/jimmunol.164.6.3112 10.1158/0008-5472.CAN-04-2059 10.1038/nrc1388 10.1016/j.immuni.2019.04.010 10.1158/2326-6066.CIR-15-0015 10.1373/clinchem.2011.171637 10.1038/labinvest.3700482 10.1016/j.celrep.2018.12.036 10.1146/annurev-immunol-031210-101324 10.4049/jimmunol.1601359 10.18632/oncotarget.6125 10.1186/bcr3665 10.1038/ni.3201 10.1158/0008-5472.CAN-11-1466 10.1046/j.1365-2141.2002.03879.x 10.4049/jimmunol.1101845 10.1038/bjc.2015.193 10.1158/1078-0432.CCR-18-1139 10.1016/j.it.2004.02.006 10.1084/jem.20021897 10.1158/0008-5472.CAN-15-1320 10.1186/s40425-017-0294-6 10.1038/srep45593 10.4161/onci.26663 10.1016/j.canlet.2008.04.050 10.18632/oncotarget.16628 10.1016/S0140-6736(00)04046-0 10.1007/s10585-007-9097-3 10.1038/35065016 10.1084/jem.178.3.1057 10.1158/0008-5472.CAN-03-1757 10.1136/jcp.2005.032144 10.1016/j.cytogfr.2012.08.007 10.1111/j.1440-1827.2010.02548.x 10.1016/S0140-6736(18)30789-X 10.3109/10428194.2016.1151511 10.1038/sj.onc.1210267 10.1016/j.cell.2017.08.027 10.1245/s10434-011-1774-4 10.1016/j.jneuroim.2008.04.029 10.1084/jem.20052144 10.1038/nm.3708
ContentType	Journal Article
Copyright	2020 Society for Leukocyte Biology 2020 Society for Leukocyte Biology.
Copyright_xml	– notice: 2020 Society for Leukocyte Biology – notice: 2020 Society for Leukocyte Biology.
DBID	AAYXX CITATION CGR CUY CVF ECM EIF NPM 7QL 7T5 7T7 7U9 8FD C1K FR3 H94 M7N P64 7X8
DOI	10.1002/JLB.5MR0320-205R
DatabaseName	CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed Bacteriology Abstracts (Microbiology B) Immunology Abstracts Industrial and Applied Microbiology Abstracts (Microbiology A) Virology and AIDS Abstracts Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database AIDS and Cancer Research Abstracts Algology Mycology and Protozoology Abstracts (Microbiology C) Biotechnology and BioEngineering Abstracts MEDLINE - Academic
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Virology and AIDS Abstracts Technology Research Database Bacteriology Abstracts (Microbiology B) Algology Mycology and Protozoology Abstracts (Microbiology C) AIDS and Cancer Research Abstracts Immunology Abstracts Engineering Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic Virology and AIDS Abstracts MEDLINE CrossRef
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Anatomy & Physiology Biology
EISSN	1938-3673
EndPage	685
ExternalDocumentID	32745326 10_1002_JLB_5MR0320_205R JLB10655
Genre	reviewArticle Research Support, Non-U.S. Gov't Journal Article Review
GroupedDBID	--- .GJ 0R~ 0VX 18M 1OB 1OC 29K 2WC 33P 4.4 53G 5GY 5RE 5WD AABZA AACZT AAHHS AAPGJ AAPXW AARHZ AASGY AAUAY AAVAP AAWDT AAXRX AAZKR ABCUV ABDFA ABEFU ABEJV ABJNI ABLJU ABMNT ABNHQ ABPQP ABPTD ABWST ABXVV ACAHQ ACCFJ ACCZN ACFRR ACGFO ACGFS ACPOU ACPRK ACUTJ ACXBN ACXQS ACZBC ADBBV ADIPN ADKYN ADOZA ADQBN ADVEK ADVOB ADXAS ADZMN AEEZP AENEX AEQDE AFFNX AFGWE AFRAH AFYAG AGMDO AGQXC AHMMS AI. AIURR AIWBW AJAOE AJBDE AJEEA ALMA_UNASSIGNED_HOLDINGS ALUQN AMYDB ANFBD APJGH ATGXG AVNTJ BCRHZ C45 CS3 D-I DCZOG DRFUL DRSTM DU5 E3Z EBS EJD EMOBN F5P F9R GX1 H13 HZ~ K-O KOP L7B LATKE LEEKS LUTES LYRES O9- OBOKY OCZFY OJZSN OK1 OPAEJ OVD OWPYF P2P P2W RHI RJQFR ROL ROX SJN SUPJJ TCN TEORI TMA TR2 TSL VH1 W8F WOHZO WOQ YHG ZGI ZXP ZZTAW AAMMB AAYXX ABGNP ABVGC ABXZS ADGKP ADNBA AEFGJ AGXDD AIDQK AIDYY AJBYB AJNCP ALXQX CITATION AFFQV CGR CUY CVF ECM EIF NPM PKN 7QL 7T5 7T7 7U9 8FD AGORE C1K FR3 H94 M7N P64 7X8
ID	FETCH-LOGICAL-c4405-f1f6d253bb522b5536c1818f12acca841117623148048c1ab6382e47df223313
IEDL.DBID	DRFUL
ISICitedReferencesCount	29
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000554805200020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	0741-5400 1938-3673
IngestDate	Sun Sep 28 11:03:48 EDT 2025 Fri Sep 12 16:40:22 EDT 2025 Wed Feb 19 02:30:18 EST 2025 Sat Nov 29 01:45:07 EST 2025 Tue Nov 18 21:17:29 EST 2025 Wed Jan 22 16:34:36 EST 2025
IsPeerReviewed	true
IsScholarly	true
Issue	2
Keywords	CXCL10 anti-tumor immunity chemokines immune suppression cancer immunotherapy lymphocyte migration
Language	English
License	https://academic.oup.com/pages/standard-publication-reuse-rights 2020 Society for Leukocyte Biology.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c4405-f1f6d253bb522b5536c1818f12acca841117623148048c1ab6382e47df223313
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 ObjectType-Review-3 content type line 23
ORCID	0000-0002-3705-2598
PMID	32745326
PQID	3248791683
PQPubID	2046249
PageCount	13
ParticipantIDs	proquest_miscellaneous_2430374369 proquest_journals_3248791683 pubmed_primary_32745326 crossref_citationtrail_10_1002_JLB_5MR0320_205R crossref_primary_10_1002_JLB_5MR0320_205R wiley_primary_10_1002_JLB_5MR0320_205R_JLB10655
PublicationCentury	2000
PublicationDate	August 2020 2020-08-01 2020-08-00 20200801
PublicationDateYYYYMMDD	2020-08-01
PublicationDate_xml	– month: 08 year: 2020 text: August 2020
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States – name: Bethesda
PublicationTitle	Journal of leukocyte biology
PublicationTitleAlternate	J Leukoc Biol
PublicationYear	2020
Publisher	Oxford University Press
Publisher_xml	– name: Oxford University Press
References	2013; 4 2013; 2 2010; 107 1997; 272 2010; 17 2010; 106 2004; 25 2015; 75 2004; 4 2000; 95 2006; 176 2009; 113 2012; 19 2019; 449 2010; 184 2012; 14 2004; 207 2012; 12 2012; 11 2011; 475 2011; 474 2014; 20 2001; 410 2007; 179 2018; 5 2019; 20 2010; 29 2005; 103 2011; 71 2004; 173 2019; 26 2004; 171 2014; 16 2008; 25 2014; 14 2007; 60 2008; 199 2006; 203 2008; 111 2007; 67 2013; 190 2001; 54 2014; 124 2019; 7 2009; 69 2019; 9 2012; 188 2007; 204 2011; 2 2006; 55 2019; 35 2005; 114 2005; 116 2010; 285 2015; 527 2012; 33 2012; 31 2011; 132 2012; 109 2018; 24 2001; 276 2016; 5 2018; 18 2016; 7 2011; 307 2006; 42 2003; 348 2017; 58 2015; 113 2002; 62 2015; 64 2019; 48 2016; 20 2009; 100 2020; 26 2011; 89 2008; 40 2017; 5 2017; 7 2004; 64 2017; 8 2010; 59 2019; 50 2013; 24 2015; 30 1996; 184 2016; 101 2011; 11 2008; 8 2013; 168 2002; 119 2015; 107 2007; 30 2019; 129 2008; 267 2017; 198 2012; 58 2017; 9 2003; 197 2010; 60 2013; 19 2012; 72 2015; 46 2014; 5 2018; 371 2013; 439 2016; 90 2006; 66 2018; 70 2008; 68 2000; 164 2003; 82 2011; 29 2012; 66 2016; 197 1993; 178 2007; 26 2014; 515 2006; 91 2015; 6 2015; 16 2015; 3 2010; 127 2015; 10 2017; 170 2018; 63 2014; 192 1993; 268 2006; 313 2014; 232 2015; 8 2014; 88 2016; 57 2004; 10 2011; 104 2018; 391 2006; 86 2012; 3 2004; 92 2010; 138 2007; 110 2015; 21 2005; 206 2016; 63 2009; 8 2012; 7 2001; 357 Romero (2023032108171750800_jlb10655-cit-0021) 2020; 26 Fridman (2023032108171750800_jlb10655-cit-0037) 2012; 12 Facciabene (2023032108171750800_jlb10655-cit-0075) 2011; 475 Wu (2023032108171750800_jlb10655-cit-0090) 2012; 11 Antonangeli (2023032108171750800_jlb10655-cit-0150) 2016; 5 Fionda (2023032108171750800_jlb10655-cit-0151) 2018; 70 Romagnani (2023032108171750800_jlb10655-cit-0016) 2004; 25 Song (2023032108171750800_jlb10655-cit-0028) 2012; 7 Kawada (2023032108171750800_jlb10655-cit-0088) 2007; 26 Sfriso (2023032108171750800_jlb10655-cit-0119) 2006; 176 Loos (2023032108171750800_jlb10655-cit-0007) 2006; 86 Herbst (2023032108171750800_jlb10655-cit-0056) 2014; 515 Monteagudo (2023032108171750800_jlb10655-cit-0098) 2007; 60 Liu (2023032108171750800_jlb10655-cit-0073) 2011; 2 Butler (2023032108171750800_jlb10655-cit-0077) 2017; 7 Ma (2023032108171750800_jlb10655-cit-0109) 2015; 30 Teichmann (2023032108171750800_jlb10655-cit-0013) 2005; 206 Wennerberg (2023032108171750800_jlb10655-cit-0014) 2015; 64 Alici (2023032108171750800_jlb10655-cit-0147) 2008; 111 Garcia (2023032108171750800_jlb10655-cit-0011) 2019; 26 Li (2023032108171750800_jlb10655-cit-0015) 2018; 24 Venetz (2023032108171750800_jlb10655-cit-0103) 2010; 127 Zagzag (2023032108171750800_jlb10655-cit-0135) 2006; 86 Liu (2023032108171750800_jlb10655-cit-0020) 2016; 7 Frohn (2023032108171750800_jlb10655-cit-0146) 2002; 119 Ohmori (2023032108171750800_jlb10655-cit-0003) 1993; 268 Shiels (2023032108171750800_jlb10655-cit-0023) 2015; 107 Loetscher (2023032108171750800_jlb10655-cit-0108) 1996; 184 Wendel (2023032108171750800_jlb10655-cit-0039) 2008; 68 Walser (2023032108171750800_jlb10655-cit-0048) 2007; 30 Dangaj (2023032108171750800_jlb10655-cit-0017) 2019; 35 Vandercappellen (2023032108171750800_jlb10655-cit-0082) 2008; 267 Barretina (2023032108171750800_jlb10655-cit-0140) 2003; 82 Bernardini (2023032108171750800_jlb10655-cit-0155) 2017; 58 Sun (2023032108171750800_jlb10655-cit-0094) 2016; 20 Davids (2023032108171750800_jlb10655-cit-0106) 2012; 3 Hong (2023032108171750800_jlb10655-cit-0049) 2011; 71 Cambien (2023032108171750800_jlb10655-cit-0101) 2009; 100 Giuliani (2023032108171750800_jlb10655-cit-0152) 2006; 91 Amatschek (2023032108171750800_jlb10655-cit-0097) 2011; 104 Luster (2023032108171750800_jlb10655-cit-0012) 1993; 178 Lau (2023032108171750800_jlb10655-cit-0127) 2014; 232 Boissonnas (2023032108171750800_jlb10655-cit-0045) 2007; 204 Burns (2023032108171750800_jlb10655-cit-0121) 2006; 203 Petrai (2023032108171750800_jlb10655-cit-0111) 2008; 40 Barreira da Silva (2023032108171750800_jlb10655-cit-0054) 2015; 16 Haabeth (2023032108171750800_jlb10655-cit-0104) 2011; 2 Sun (2023032108171750800_jlb10655-cit-0123) 2010; 29 Robledo (2023032108171750800_jlb10655-cit-0085) 2001; 276 Cancer Genome Atlas Research (2023032108171750800_jlb10655-cit-0018) 2011; 474 Kuo (2023032108171750800_jlb10655-cit-0118) 2018; 5 Ding (2023032108171750800_jlb10655-cit-0093) 2016; 7 Visvader (2023032108171750800_jlb10655-cit-0122) 2008; 8 Pages (2023032108171750800_jlb10655-cit-0036) 2018; 391 Nakanishi (2023032108171750800_jlb10655-cit-0087) 2006; 55 Yang (2023032108171750800_jlb10655-cit-0125) 2011; 89 Klee (2023032108171750800_jlb10655-cit-0126) 2012; 58 Wightman (2023032108171750800_jlb10655-cit-0100) 2015; 113 Hu (2023032108171750800_jlb10655-cit-0113) 2015; 46 Jin (2023032108171750800_jlb10655-cit-0136) 2018; 371 Utsumi (2023032108171750800_jlb10655-cit-0092) 2014; 192 Wong (2023032108171750800_jlb10655-cit-0134) 2014; 14 Sen (2023032108171750800_jlb10655-cit-0006) 2019; 9 Curiel (2023032108171750800_jlb10655-cit-0074) 2004; 10 Berchiche (2023032108171750800_jlb10655-cit-0107) 2016; 90 Goodyear (2023032108171750800_jlb10655-cit-0145) 2017; 8 Maingat (2023032108171750800_jlb10655-cit-0008) 2010; 184 Lunardi (2023032108171750800_jlb10655-cit-0019) 2014; 5 Han (2023032108171750800_jlb10655-cit-0066) 2019; 48 Zlotnik (2023032108171750800_jlb10655-cit-0083) 2011; 11 Galon (2023032108171750800_jlb10655-cit-0034) 2006; 313 Wang (2023032108171750800_jlb10655-cit-0070) 2013; 439 Bolitho (2023032108171750800_jlb10655-cit-0025) 2010; 17 Ribas (2023032108171750800_jlb10655-cit-0062) 2017; 170 Mlecnik (2023032108171750800_jlb10655-cit-0043) 2010; 138 Zhang (2023032108171750800_jlb10655-cit-0032) 2019; 449 Meares (2023032108171750800_jlb10655-cit-0010) 2013; 190 Furusato (2023032108171750800_jlb10655-cit-0124) 2010; 60 Reckamp (2023032108171750800_jlb10655-cit-0161) 2007; 30 Singh (2023032108171750800_jlb10655-cit-0133) 2013; 24 Leivas (2023032108171750800_jlb10655-cit-0149) 2016; 5 Sahraei (2023032108171750800_jlb10655-cit-0071) 2019; 129 Chen (2023032108171750800_jlb10655-cit-0072) 2017; 9 Datta (2023032108171750800_jlb10655-cit-0112) 2010; 285 Wani (2023032108171750800_jlb10655-cit-0026) 2014; 16 Balkwill (2023032108171750800_jlb10655-cit-0079) 2004; 4 Pellegrino (2023032108171750800_jlb10655-cit-0115) 2004; 207 Sistigu (2023032108171750800_jlb10655-cit-0050) 2014; 20 Ajina (2023032108171750800_jlb10655-cit-0060) 2017; 5 Wu (2023032108171750800_jlb10655-cit-0091) 2012; 66 Zhang (2023032108171750800_jlb10655-cit-0035) 2003; 348 Peng (2023032108171750800_jlb10655-cit-0057) 2012; 72 Petro (2023032108171750800_jlb10655-cit-0064) 2013; 190 Zipin-Roitman (2023032108171750800_jlb10655-cit-0095) 2007; 67 Yopp (2023032108171750800_jlb10655-cit-0138) 2012; 19 Goldberg-Bittman (2023032108171750800_jlb10655-cit-0086) 2004; 92 Harlin (2023032108171750800_jlb10655-cit-0002) 2009; 69 Korniejewska (2023032108171750800_jlb10655-cit-0117) 2011; 132 Maru (2023032108171750800_jlb10655-cit-0110) 2008; 199 Lasagni (2023032108171750800_jlb10655-cit-0114) 2003; 197 Ben-Baruch (2023032108171750800_jlb10655-cit-0080) 2008; 25 Giegold (2023032108171750800_jlb10655-cit-0143) 2013; 190 Cekic (2023032108171750800_jlb10655-cit-0068) 2012; 188 Kawada (2023032108171750800_jlb10655-cit-0137) 2011; 71 Ohmori (2023032108171750800_jlb10655-cit-0004) 1997; 272 Brownell (2023032108171750800_jlb10655-cit-0005) 2014; 88 Redjimi (2023032108171750800_jlb10655-cit-0033) 2012; 72 O'Boyle (2023032108171750800_jlb10655-cit-0142) 2012; 109 Su (2023032108171750800_jlb10655-cit-0027) 2011; 307 Li (2023032108171750800_jlb10655-cit-0041) 2015; 8 Frelaut (2023032108171750800_jlb10655-cit-0065) 2019; 20 Chow (2023032108171750800_jlb10655-cit-0059) 2019; 50 Bolomsky (2023032108171750800_jlb10655-cit-0153) 2016; 57 Metzemaekers (2023032108171750800_jlb10655-cit-0052) 2017; 8 Suyama (2023032108171750800_jlb10655-cit-0030) 2005; 103 Dorsey (2023032108171750800_jlb10655-cit-0047) 2002; 62 Benigni (2023032108171750800_jlb10655-cit-0157) 2017; 198 Bronger (2023032108171750800_jlb10655-cit-0009) 2012; 14 Zhang (2023032108171750800_jlb10655-cit-0031) 2018; 18 Narvaiza (2023032108171750800_jlb10655-cit-0046) 2000; 164 Suefuji (2023032108171750800_jlb10655-cit-0102) 2005; 114 Keeley (2023032108171750800_jlb10655-cit-0081) 2010; 106 Ganghammer (2023032108171750800_jlb10655-cit-0139) 2016; 101 Tokunaga (2023032108171750800_jlb10655-cit-0022) 2018; 63 Balkwill (2023032108171750800_jlb10655-cit-0078) 2001; 357 Ponzetta (2023032108171750800_jlb10655-cit-0144) 2015; 75 Zhu (2023032108171750800_jlb10655-cit-0061) 2010; 59 Zhu (2023032108171750800_jlb10655-cit-0096) 2015; 6 Jones (2023032108171750800_jlb10655-cit-0084) 2000; 95 San-Miguel (2023032108171750800_jlb10655-cit-0128) 2015; 21 Nishina (2023032108171750800_jlb10655-cit-0055) 2019; 7 Vesely (2023032108171750800_jlb10655-cit-0076) 2011; 29 Narita (2023032108171750800_jlb10655-cit-0129) 2016; 63 Watts (2023032108171750800_jlb10655-cit-0141) 2013; 168 Mulligan (2023032108171750800_jlb10655-cit-0024) 2013; 19 Muller (2023032108171750800_jlb10655-cit-0120) 2001; 410 Watanabe (2023032108171750800_jlb10655-cit-0154) 2015; 10 Ma (2023032108171750800_jlb10655-cit-0089) 2009; 8 Bonanni (2023032108171750800_jlb10655-cit-0158) 2019; 7 Peng (2023032108171750800_jlb10655-cit-0067) 2015; 527 Ehlert (2023032108171750800_jlb10655-cit-0116) 2004; 173 Kondo (2023032108171750800_jlb10655-cit-0063) 2004; 171 Clancy-Thompson (2023032108171750800_jlb10655-cit-0069) 2015; 3 Levoye (2023032108171750800_jlb10655-cit-0130) 2009; 113 Strieter (2023032108171750800_jlb10655-cit-0044) 2006; 42 Bernardini (2023032108171750800_jlb10655-cit-0156) 2013; 4 Gorrell (2023032108171750800_jlb10655-cit-0053) 2001; 54 Winter (2023032108171750800_jlb10655-cit-0105) 2007; 179 Rajagopal (2023032108171750800_jlb10655-cit-0132) 2010; 107 Soriani (2023032108171750800_jlb10655-cit-0148) 2013; 2 Li (2023032108171750800_jlb10655-cit-0160) 2016; 5 Mullins (2023032108171750800_jlb10655-cit-0040) 2004; 64 Viola (2023032108171750800_jlb10655-cit-0001) 2012; 33 Luker (2023032108171750800_jlb10655-cit-0131) 2012; 31 Musha (2023032108171750800_jlb10655-cit-0099) 2005; 116 Kawada (2023032108171750800_jlb10655-cit-0029) 2004; 64 Walser (2023032108171750800_jlb10655-cit-0038) 2006; 66 Mikucki (2023032108171750800_jlb10655-cit-0042) 2015; 6 Chheda (2023032108171750800_jlb10655-cit-0058) 2016; 197 Proost (2023032108171750800_jlb10655-cit-0051) 2007; 110 Zohar (2023032108171750800_jlb10655-cit-0159) 2014; 124
References_xml	– volume: 35 start-page: 885 issue: 6 year: 2019 end-page: 900.e10 article-title: Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors publication-title: Cancer Cell – volume: 168 start-page: 1662 issue: 7 year: 2013 end-page: 1674 article-title: Identification and profiling of CXCR3‐CXCR4 chemokine receptor heteromer complexes publication-title: Br J Pharmacol – volume: 9 start-page: 646 issue: 5 year: 2019 end-page: 661 article-title: Targeting DNA damage response promotes antitumor immunity through STING‐mediated T‐cell activation in small cell lung cancer publication-title: Cancer Discov – volume: 26 start-page: 192 issue: 1 year: 2019 end-page: 208.e6 article-title: Genetic liver‐specific AMPK activation protects against diet‐induced obesity and NAFLD publication-title: Cell Rep – volume: 113 start-page: 6085 issue: 24 year: 2009 end-page: 6093 article-title: CXCR7 heterodimerizes with CXCR4 and regulates CXCL12‐mediated G protein signaling publication-title: Blood – volume: 7 year: 2017 article-title: CXCR3(+) monocytes/macrophages are required for establishment of pulmonary metastases publication-title: Sci Rep – volume: 68 start-page: 8437 issue: 20 year: 2008 end-page: 8445 article-title: Natural killer cell accumulation in tumors is dependent on IFN‐gamma and CXCR3 ligands publication-title: Cancer Res – volume: 475 start-page: 226 issue: 7355 year: 2011 end-page: 230 article-title: Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells publication-title: Nature – volume: 104 start-page: 469 issue: 3 year: 2011 end-page: 479 article-title: CXCL9 induces chemotaxis, chemorepulsion and endothelial barrier disruption through CXCR3‐mediated activation of melanoma cells publication-title: Br J Cancer – volume: 90 start-page: 483 issue: 4 year: 2016 end-page: 495 article-title: CXC chemokine receptor 3 alternative splice variants selectively activate different signaling pathways publication-title: Mol Pharmacol – volume: 14 start-page: 12 year: 2014 article-title: Targeting CXCR4 with CTCE‐9908 inhibits prostate tumor metastasis publication-title: BMC Urol – volume: 184 start-page: 1566 issue: 3 year: 2010 end-page: 1574 article-title: Regulation of lentivirus neurovirulence by lipopolysaccharide conditioning: suppression of CXCL10 in the brain by IL‐10 publication-title: J Immunol – volume: 17 start-page: 929 issue: 4 year: 2010 end-page: 940 article-title: The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor publication-title: Endocr Relat Cancer – volume: 110 start-page: 37 issue: 1 year: 2007 end-page: 44 article-title: Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration publication-title: Blood – volume: 25 start-page: 345 issue: 4 year: 2008 end-page: 356 article-title: Organ selectivity in metastasis: regulation by chemokines and their receptors publication-title: Clin Exp Metastasis – volume: 179 start-page: 4272 issue: 6 year: 2007 end-page: 4282 article-title: Down‐modulation of CXCR3 surface expression and function in CD8+ T cells from cutaneous T cell lymphoma patients publication-title: J Immunol – volume: 30 start-page: 490 issue: 5 year: 2007 end-page: 498 article-title: Immune‐mediated modulation of breast cancer growth and metastasis by the chemokine Mig (CXCL9) in a murine model publication-title: J Immunother – volume: 63 start-page: 141 issue: 1 year: 2016 end-page: 149 article-title: Altered levels of plasma chemokines in breast cancer and their association with clinical and pathological characteristics publication-title: Neoplasma – volume: 107 issue: 10 year: 2015 article-title: Circulating inflammation markers, risk of lung cancer, and utility for risk stratification publication-title: J Natl Cancer Inst – volume: 2 issue: 12 year: 2013 article-title: Chemotherapy‐elicited upregulation of NKG2D and DNAM‐1 ligands as a therapeutic target in multiple myeloma publication-title: Oncoimmunology – volume: 12 start-page: 298 issue: 4 year: 2012 end-page: 306 article-title: The immune contexture in human tumours: impact on clinical outcome publication-title: Nat Rev Cancer – volume: 14 start-page: R30 issue: 1 year: 2012 article-title: Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer publication-title: Breast Cancer Res – volume: 67 start-page: 3396 issue: 7 year: 2007 end-page: 3405 article-title: CXCL10 promotes invasion‐related properties in human colorectal carcinoma cells publication-title: Cancer Res – volume: 58 start-page: 599 issue: 3 year: 2012 end-page: 609 article-title: Candidate serum biomarkers for prostate adenocarcinoma identified by mRNA differences in prostate tissue and verified with protein measurements in tissue and blood publication-title: Clin Chem – volume: 7 issue: 5 year: 2012 article-title: Deficiency of C‐C chemokine receptor 5 suppresses tumor development via inactivation of NF‐kappaB and upregulation of IL‐1Ra in melanoma model publication-title: PLoS One – volume: 5 issue: 2 year: 2016 article-title: Hydrogel dual delivered celecoxib and anti‐PD‐1 synergistically improve antitumor immunity publication-title: Oncoimmunology – volume: 64 start-page: 7697 issue: 21 year: 2004 end-page: 7701 article-title: CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease publication-title: Cancer Res – volume: 21 start-page: 1191 issue: 4 year: 2015 end-page: 1199 article-title: Expression of the chemokine receptors CXCR3, CXCR4, CXCR7 and their ligands in rhabdomyosarcoma publication-title: Pathol Oncol Res – volume: 8 start-page: 30383 issue: 18 year: 2017 end-page: 30394 article-title: Neoplastic plasma cells generate an inflammatory environment within bone marrow and markedly alter the distribution of T cells between lymphoid compartments publication-title: Oncotarget – volume: 170 start-page: 1109 issue: 6 year: 2017 end-page: 1119.e10 article-title: Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti‐PD‐1 immunotherapy publication-title: Cell – volume: 176 start-page: 2581 issue: 4 year: 2006 end-page: 2589 article-title: Epithelial CXCR3‐B regulates chemokines bioavailability in normal, but not in Sjogren's syndrome, salivary glands publication-title: J Immunol – volume: 9 start-page: 4308 issue: 9 year: 2017 end-page: 4316 article-title: MiR‐15a‐5p negatively regulates cell survival and metastasis by targeting CXCL10 in chronic myeloid leukemia publication-title: Am J Transl Res – volume: 92 start-page: 171 issue: 1‐2 year: 2004 end-page: 178 article-title: The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines publication-title: Immunol Lett – volume: 89 start-page: 85 issue: 1 year: 2011 end-page: 91 article-title: Foxp3+IL‐17+ T cells promote development of cancer‐initiating cells in colorectal cancer publication-title: J Leukoc Biol – volume: 54 start-page: 249 issue: 3 year: 2001 end-page: 264 article-title: CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes publication-title: Scand J Immunol – volume: 7 start-page: 115 issue: 1 year: 2019 end-page: 134 article-title: Dipeptidyl peptidase 4 inhibitors reduce hepatocellular carcinoma by activating lymphocyte chemotaxis in mice publication-title: Cell Mol Gastroenterol Hepatol – volume: 119 start-page: 660 issue: 3 year: 2002 end-page: 664 article-title: Anti‐myeloma activity of natural killer lymphocytes publication-title: Br J Haematol – volume: 114 start-page: 896 issue: 6 year: 2005 end-page: 901 article-title: CXCR3‐positive B cells found at elevated frequency in the peripheral blood of patients with MALT lymphoma are attracted by MIG and belong to the lymphoma clone publication-title: Int J Cancer – volume: 6 start-page: 7458 year: 2015 article-title: Non‐redundant requirement for CXCR3 signalling during tumoricidal T‐cell trafficking across tumour vascular checkpoints publication-title: Nat Commun – volume: 206 start-page: 68 issue: 1 year: 2005 end-page: 75 article-title: Expression of the interferon‐inducible chemokine IP‐10 (CXCL10), a chemokine with proposed anti‐neoplastic functions, in Hodgkin lymphoma and nasopharyngeal carcinoma publication-title: J Pathol – volume: 11 start-page: 597 issue: 9 year: 2011 end-page: 606 article-title: Homeostatic chemokine receptors and organ‐specific metastasis publication-title: Nat Rev Immunol – volume: 63 start-page: 40 year: 2018 end-page: 47 article-title: CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation ‐ A target for novel cancer therapy publication-title: Cancer Treat Rev – volume: 29 start-page: 235 year: 2011 end-page: 271 article-title: Natural innate and adaptive immunity to cancer publication-title: Annu Rev Immunol – volume: 103 start-page: 258 issue: 2 year: 2005 end-page: 267 article-title: Up‐regulation of the interferon gamma (IFN‐gamma)‐inducible chemokines IFN‐inducible T‐cell alpha chemoattractant and monokine induced by IFN‐gamma and of their receptor CXC receptor 3 in human renal cell carcinoma publication-title: Cancer – volume: 267 start-page: 226 issue: 2 year: 2008 end-page: 244 article-title: The role of CXC chemokines and their receptors in cancer publication-title: Cancer Lett – volume: 58 start-page: 2493 issue: 10 year: 2017 end-page: 2496 article-title: High expression levels of IP10/CXCL10 are associated with modulation of the natural killer cell compartment in multiple myeloma publication-title: Leuk Lymphoma – volume: 24 start-page: 41 issue: 1 year: 2013 end-page: 49 article-title: Chemokine receptor trio: cXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12 publication-title: Cytokine Growth Factor Rev – volume: 8 start-page: 490 issue: 3 year: 2009 end-page: 498 article-title: CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model publication-title: Mol Cancer Ther – volume: 91 start-page: 1489 issue: 11 year: 2006 end-page: 1497 article-title: CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival publication-title: Haematologica – volume: 24 start-page: 6447 issue: 24 year: 2018 end-page: 6458 article-title: IFNgamma‐induced chemokines are required for CXCR3‐mediated T‐Cell recruitment and antitumor efficacy of anti‐HER2/CD3 bispecific antibody publication-title: Clin Cancer Res – volume: 62 start-page: 2606 issue: 9 year: 2002 end-page: 2610 article-title: Immunotherapy with interleukin‐10 depends on the CXC chemokines inducible protein‐10 and monokine induced by IFN‐gamma publication-title: Cancer Res – volume: 64 start-page: 225 issue: 2 year: 2015 end-page: 235 article-title: CXCL10‐induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo publication-title: Cancer Immunol Immunother – volume: 127 start-page: 2300 issue: 10 year: 2010 end-page: 2312 article-title: Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: t‐cell infiltration and positioning of malignant B cells publication-title: Int J Cancer – volume: 5 start-page: 271 year: 2018 article-title: The role of CXCR3 and its chemokine ligands in skin disease and cancer publication-title: Front Med (Lausanne) – volume: 197 start-page: 2016 issue: 5 year: 2016 end-page: 2026 article-title: Chemoattractant receptors BLT1 and CXCR3 regulate antitumor immunity by facilitating CD8+ T cell migration into tumors publication-title: J Immunol – volume: 26 start-page: 4679 issue: 32 year: 2007 end-page: 4688 article-title: Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes publication-title: Oncogene – volume: 391 start-page: 2128 issue: 10135 year: 2018 end-page: 2139 article-title: International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study publication-title: Lancet – volume: 132 start-page: 503 issue: 4 year: 2011 end-page: 515 article-title: Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes publication-title: Immunology – volume: 48 start-page: 169 year: 2019 end-page: 177 article-title: Role of CXCR3 signaling in response to anti‐PD‐1 therapy publication-title: EBioMedicine – volume: 276 start-page: 45098 issue: 48 year: 2001 end-page: 45105 article-title: Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells publication-title: J Biol Chem – volume: 82 start-page: 500 issue: 8 year: 2003 end-page: 505 article-title: CXCR4 and SDF‐1 expression in B‐cell chronic lymphocytic leukemia and stage of the disease publication-title: Ann Hematol – volume: 16 start-page: 850 issue: 8 year: 2015 end-page: 858 article-title: Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy publication-title: Nat Immunol – volume: 2 start-page: 583 issue: 4 year: 2011 end-page: 589 article-title: The emerging role of CXCL10 in cancer (Review) publication-title: Oncol Lett – volume: 10 issue: 6 year: 2015 article-title: Lipopolysaccharide‐induced CXCL10 mRNA level and six stimulant‐mRNA combinations in whole blood: novel biomarkers for Bortezomib responses obtained from a prospective multicenter trial for patients with multiple myeloma publication-title: PLoS One – volume: 313 start-page: 1960 issue: 5795 year: 2006 end-page: 1964 article-title: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome publication-title: Science – volume: 138 start-page: 1429 issue: 4 year: 2010 end-page: 1440 article-title: Biomolecular network reconstruction identifies T‐cell homing factors associated with survival in colorectal cancer publication-title: Gastroenterology – volume: 31 start-page: 4750 issue: 45 year: 2012 end-page: 4758 article-title: Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4‐positive breast cancer cells publication-title: Oncogene – volume: 198 start-page: 2115 issue: 5 year: 2017 end-page: 2124 article-title: CXCR3/CXCL10 Axis Regulates Neutrophil‐NK cell cross‐talk determining the severity of experimental osteoarthritis publication-title: J Immunol – volume: 6 start-page: 43408 issue: 41 year: 2015 end-page: 43419 article-title: CXCR3 as a molecular target in breast cancer metastasis: inhibition of tumor cell migration and promotion of host anti‐tumor immunity publication-title: Oncotarget – volume: 178 start-page: 1057 issue: 3 year: 1993 end-page: 1065 article-title: IP‐10, a ‐C‐X‐C‐ chemokine, elicits a potent thymus‐dependent antitumor response in vivo publication-title: J Exp Med – volume: 64 start-page: 4010 issue: 11 year: 2004 end-page: 4017 article-title: Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes publication-title: Cancer Res – volume: 173 start-page: 6234 issue: 10 year: 2004 end-page: 6240 article-title: Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping publication-title: J Immunol – volume: 285 start-page: 36842 issue: 47 year: 2010 end-page: 36848 article-title: CXCR3‐B can mediate growth‐inhibitory signals in human renal cancer cells by down‐regulating the expression of heme oxygenase‐1 publication-title: J Biol Chem – volume: 20 issue: 11 year: 2019 article-title: Hyperprogression under immunotherapy publication-title: Int J Mol Sci – volume: 190 start-page: 832 issue: 2 year: 2013 end-page: 841 article-title: Cutaneous tumors cease CXCL9/Mig production as a result of IFN‐gamma‐mediated immunoediting publication-title: J Immunol – volume: 439 start-page: 384 issue: 3 year: 2013 end-page: 389 article-title: miRNA‐21 inhibition enhances RANTES and IP‐10 release in MCF‐7 via PIAS3 and STAT3 signalling and causes increased lymphocyte migration publication-title: Biochem Biophys Res Commun – volume: 7 start-page: 13976 issue: 12 year: 2016 end-page: 13983 article-title: Elevated expression of IFN‐inducible CXCR3 ligands predicts poor prognosis in patients with non‐metastatic clear‐cell renal cell carcinoma publication-title: Oncotarget – volume: 348 start-page: 203 issue: 3 year: 2003 end-page: 213 article-title: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer publication-title: N Engl J Med – volume: 8 start-page: 755 issue: 10 year: 2008 end-page: 768 article-title: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions publication-title: Nat Rev Cancer – volume: 10 start-page: 942 issue: 9 year: 2004 end-page: 949 article-title: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival publication-title: Nat Med – volume: 272 start-page: 14899 issue: 23 year: 1997 end-page: 14907 article-title: Synergy between interferon‐gamma and tumor necrosis factor‐alpha in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kappaB publication-title: J Biol Chem – volume: 8 start-page: 14725 issue: 11 year: 2015 end-page: 14732 article-title: Impact of chemokine receptor CXCR3 on tumor‐infiltrating lymphocyte recruitment associated with favorable prognosis in advanced gastric cancer publication-title: Int J Clin Exp Pathol – volume: 124 start-page: 2009 issue: 5 year: 2014 end-page: 2022 article-title: CXCL11‐dependent induction of FOXP3‐negative regulatory T cells suppresses autoimmune encephalomyelitis publication-title: J Clin Invest – volume: 33 start-page: 496 issue: 10 year: 2012 end-page: 504 article-title: The pros and cons of chemokines in tumor immunology publication-title: Trends Immunol – volume: 18 start-page: 462 issue: 1 year: 2018 article-title: CXCL9/10/11, a regulator of PD‐L1 expression in gastric cancer publication-title: BMC Cancer – volume: 95 start-page: 627 issue: 2 year: 2000 end-page: 632 article-title: The chemokine receptor CXCR3 is expressed in a subset of B‐cell lymphomas and is a marker of B‐cell chronic lymphocytic leukemia publication-title: Blood – volume: 100 start-page: 1755 issue: 11 year: 2009 end-page: 1764 article-title: Organ‐specific inhibition of metastatic colon carcinoma by CXCR3 antagonism publication-title: Br J Cancer – volume: 20 start-page: 1301 issue: 11 year: 2014 end-page: 1309 article-title: Cancer cell‐autonomous contribution of type I interferon signaling to the efficacy of chemotherapy publication-title: Nat Med – volume: 29 start-page: 709 issue: 4 year: 2010 end-page: 722 article-title: CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression publication-title: Cancer Metastasis Rev – volume: 11 start-page: 3 year: 2012 article-title: Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion publication-title: Mol Cancer – volume: 164 start-page: 3112 issue: 6 year: 2000 end-page: 3122 article-title: Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN‐gamma‐inducible protein‐10 and another encoding IL‐12, results in marked antitumoral synergy publication-title: J Immunol – volume: 190 start-page: 372 issue: 1 year: 2013 end-page: 380 article-title: AMP‐activated protein kinase restricts IFN‐gamma signaling publication-title: J Immunol – volume: 5 start-page: 11064 issue: 22 year: 2014 end-page: 11080 article-title: IP‐10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival publication-title: Oncotarget – volume: 72 start-page: 5209 issue: 20 year: 2012 end-page: 5218 article-title: PD‐1 blockade enhances T‐cell migration to tumors by elevating IFN‐gamma inducible chemokines publication-title: Cancer Res – volume: 2 start-page: 240 year: 2011 article-title: Inflammation driven by tumour‐specific Th1 cells protects against B‐cell cancer publication-title: Nat Commun – volume: 101 start-page: e99 issue: 3 year: 2016 end-page: 102 article-title: Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co‐operativity of the receptors publication-title: Haematologica – volume: 449 start-page: 163 year: 2019 end-page: 171 article-title: CXCL11 promotes self‐renewal and tumorigenicity of alpha2delta1(+) liver tumor‐initiating cells through CXCR3/ERK1/2 signaling publication-title: Cancer Lett – volume: 30 start-page: 781 issue: 7 year: 2015 end-page: 792 article-title: CXCR3 in carcinoma progression publication-title: Histol Histopathol – volume: 371 start-page: 162 issue: 1 year: 2018 end-page: 174 article-title: CXCR3 expression in colorectal cancer cells enhanced invasion through preventing CXCR4 internalization publication-title: Exp Cell Res – volume: 204 start-page: 345 issue: 2 year: 2007 end-page: 356 article-title: In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor publication-title: J Exp Med – volume: 7 start-page: 290 issue: 1 year: 2019 article-title: Targeting of CXCR3 improves anti‐myeloma efficacy of adoptively transferred activated natural killer cells publication-title: J Immunother Cancer – volume: 4 start-page: 540 issue: 7 year: 2004 end-page: 550 article-title: Cancer and the chemokine network publication-title: Nat Rev Cancer – volume: 4 start-page: 12 year: 2013 article-title: Differential chemotactic receptor requirements for NK cell subset trafficking into bone marrow publication-title: Front Immunol – volume: 71 start-page: 6997 issue: 22 year: 2011 end-page: 7009 article-title: Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T‐cell infiltration and tumor control publication-title: Cancer Res – volume: 25 start-page: 201 issue: 4 year: 2004 end-page: 209 article-title: CXC chemokines: the regulatory link between inflammation and angiogenesis publication-title: Trends Immunol – volume: 5 start-page: 90 issue: 1 year: 2017 article-title: Prospects for combined use of oncolytic viruses and CAR T‐cells publication-title: J Immunother Cancer – volume: 197 start-page: 1537 issue: 11 year: 2003 end-page: 1549 article-title: An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP‐10, Mig, and I‐TAC, and acts as functional receptor for platelet factor 4 publication-title: J Exp Med – volume: 30 start-page: 417 issue: 4 year: 2007 end-page: 424 article-title: Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL‐2 therapy publication-title: J Immunother – volume: 60 start-page: 497 issue: 7 year: 2010 end-page: 505 article-title: CXCR4 and cancer publication-title: Pathol Int – volume: 190 start-page: 3696 issue: 7 year: 2013 end-page: 3705 article-title: CXCL9 causes heterologous desensitization of CXCL12‐mediated memory T lymphocyte activation publication-title: J Immunol – volume: 171 start-page: 2171 issue: 6 Pt 1 year: 2004 end-page: 2175 article-title: High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma publication-title: J Urol – volume: 106 start-page: 91 year: 2010 end-page: 111 article-title: CXC chemokines in cancer angiogenesis and metastases publication-title: Adv Cancer Res – volume: 70 start-page: 255 year: 2018 end-page: 264 article-title: Translating the anti‐myeloma activity of natural killer cells into clinical application publication-title: Cancer Treat Rev – volume: 192 start-page: 567 issue: 2 year: 2014 end-page: 574 article-title: The association of CXCR3 and renal cell carcinoma metastasis publication-title: J Urol – volume: 111 start-page: 3155 issue: 6 year: 2008 end-page: 3162 article-title: Autologous antitumor activity by NK cells expanded from myeloma patients using GMP‐compliant components publication-title: Blood – volume: 207 start-page: 221 issue: 2 year: 2004 end-page: 227 article-title: CXCR3‐binding chemokines in multiple myeloma publication-title: Cancer Lett – volume: 50 start-page: 1498 issue: 6 year: 2019 end-page: 1512.e5 article-title: Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti‐PD‐1 therapy publication-title: Immunity – volume: 71 start-page: 1214 issue: 4 year: 2011 end-page: 1218 article-title: Significance and mechanism of lymph node metastasis in cancer progression publication-title: Cancer Res – volume: 26 start-page: 1997 year: 2020 end-page: 2010 article-title: A four‐chemokine signature is associated with a T‐cell‐inflamed phenotype in primary and metastatic pancreatic cancer publication-title: Clin Cancer Res – volume: 188 start-page: 198 issue: 1 year: 2012 end-page: 205 article-title: Adenosine A2B receptor blockade slows growth of bladder and breast tumors publication-title: J Immunol – volume: 86 start-page: 1221 issue: 12 year: 2006 end-page: 1232 article-title: Hypoxia‐inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion publication-title: Lab Invest – volume: 66 start-page: 7701 issue: 15 year: 2006 end-page: 7707 article-title: Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer publication-title: Cancer Res – volume: 16 start-page: R54 issue: 3 year: 2014 article-title: C‐X‐C motif chemokine 12/C‐X‐C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment publication-title: Breast Cancer Res – volume: 474 start-page: 609 issue: 7353 year: 2011 end-page: 615 article-title: Integrated genomic analyses of ovarian carcinoma publication-title: Nature – volume: 232 start-page: 43 issue: 1 year: 2014 end-page: 56 article-title: Cancer cell‐derived lymphotoxin mediates reciprocal tumour‐stromal interactions in human ovarian cancer by inducing CXCL11 in fibroblasts publication-title: J Pathol – volume: 109 start-page: 4598 issue: 12 year: 2012 end-page: 4603 article-title: Chemokine receptor CXCR3 agonist prevents human T‐cell migration in a humanized model of arthritic inflammation publication-title: Proc Natl Acad Sci U S A – volume: 7 start-page: 14405 issue: 12 year: 2016 end-page: 14414 article-title: An alternatively spliced variant of CXCR3 mediates the metastasis of CD133+ liver cancer cells induced by CXCL9 publication-title: Oncotarget – volume: 46 start-page: 1872 issue: 12 year: 2015 end-page: 1880 article-title: Overexpression of the chemokine receptor CXCR3 and its correlation with favorable prognosis in gastric cancer publication-title: Hum Pathol – volume: 19 start-page: 336 issue: 2 year: 2013 end-page: 346 article-title: Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry publication-title: Clin Cancer Res – volume: 307 start-page: 132 issue: 2 year: 2011 end-page: 140 article-title: Chemokine receptor CXCR4‐mediated transformation of mammary epithelial cells by enhancing multiple RTKs expression and deregulation of the p53/MDM2 axis publication-title: Cancer Lett – volume: 199 start-page: 35 issue: 1‐2 year: 2008 end-page: 45 article-title: Chemokine production and chemokine receptor expression by human glioma cells: role of CXCL10 in tumour cell proliferation publication-title: J Neuroimmunol – volume: 72 start-page: 4351 issue: 17 year: 2012 end-page: 4360 article-title: CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity publication-title: Cancer Res – volume: 66 start-page: 373 issue: 5 year: 2012 end-page: 377 article-title: The prognostic significance of chemokine receptor CXCR3 expression in colorectal carcinoma publication-title: Biomed Pharmacother – volume: 116 start-page: 949 issue: 6 year: 2005 end-page: 956 article-title: Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma publication-title: Int J Cancer – volume: 19 start-page: S339 issue: Suppl 3 year: 2012 end-page: 46 article-title: CXCR4 expression predicts patient outcome and recurrence patterns after hepatic resection for colorectal liver metastases publication-title: Ann Surg Oncol – volume: 107 start-page: 628 issue: 2 year: 2010 end-page: 632 article-title: Beta‐arrestin‐ but not G protein‐mediated signaling by the “decoy” receptor CXCR7 publication-title: Proc Natl Acad Sci U S A – volume: 184 start-page: 963 issue: 3 year: 1996 end-page: 969 article-title: Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T‐lymphocytes publication-title: J Exp Med – volume: 40 start-page: 1764 issue: 9 year: 2008 end-page: 1774 article-title: Activation of p38(MAPK) mediates the angiostatic effect of the chemokine receptor CXCR3‐B publication-title: Int J Biochem Cell Biol – volume: 86 start-page: 902 issue: 9 year: 2006 end-page: 916 article-title: TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis publication-title: Lab Invest – volume: 59 start-page: 1401 issue: 9 year: 2010 end-page: 1409 article-title: Poly‐ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN‐alpha and IFN‐gamma dependent manners publication-title: Cancer Immunol Immunother – volume: 113 start-page: 327 issue: 2 year: 2015 end-page: 335 article-title: Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome publication-title: Br J Cancer – volume: 3 issue: S1 year: 2012 article-title: Cell trafficking in chronic lymphocytic leukemia publication-title: Open J Hematol – volume: 8 start-page: 1970 year: 2017 article-title: Overview of the mechanisms that may contribute to the non‐redundant activities of interferon‐inducible CXC chemokine receptor 3 ligands publication-title: Front Immunol – volume: 5 issue: 12 year: 2016 article-title: Novel treatment strategy with autologous activated and expanded natural killer cells plus anti‐myeloma drugs for multiple myeloma publication-title: Oncoimmunology – volume: 20 start-page: 2020 issue: 11 year: 2016 end-page: 2028 article-title: TNF‐alpha augments CXCR2 and CXCR3 to promote progression of renal cell carcinoma publication-title: J Cell Mol Med – volume: 3 start-page: 956 issue: 8 year: 2015 end-page: 967 article-title: Melanoma induces, and adenosine suppresses, CXCR3‐cognate chemokine production and T‐cell infiltration of lungs bearing metastatic‐like disease publication-title: Cancer Immunol Res – volume: 57 start-page: 2516 issue: 11 year: 2016 end-page: 2525 article-title: Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma publication-title: Leuk Lymphoma – volume: 75 start-page: 4766 issue: 22 year: 2015 end-page: 4777 article-title: Multiple myeloma impairs bone marrow localization of effector natural killer cells by altering the chemokine microenvironment publication-title: Cancer Res – volume: 55 start-page: 1320 issue: 11 year: 2006 end-page: 1329 article-title: Expression of macrophage‐derived chemokine (MDC)/CCL22 in human lung cancer publication-title: Cancer Immunol Immunother – volume: 357 start-page: 539 issue: 9255 year: 2001 end-page: 545 article-title: Inflammation and cancer: back to Virchow? publication-title: Lancet – volume: 268 start-page: 6677 issue: 9 year: 1993 end-page: 6688 article-title: Cooperative interaction between interferon (IFN) stimulus response element and kappa B sequence motifs controls IFN gamma‐ and lipopolysaccharide‐stimulated transcription from the murine IP‐10 promoter publication-title: J Biol Chem – volume: 129 start-page: 5518 issue: 12 year: 2019 end-page: 5536 article-title: Suppressing miR‐21 activity in tumor‐associated macrophages promotes an antitumor immune response publication-title: J Clin Invest – volume: 527 start-page: 249 issue: 7577 year: 2015 end-page: 253 article-title: Epigenetic silencing of TH1‐type chemokines shapes tumour immunity and immunotherapy publication-title: Nature – volume: 410 start-page: 50 issue: 6824 year: 2001 end-page: 56 article-title: Involvement of chemokine receptors in breast cancer metastasis publication-title: Nature – volume: 69 start-page: 3077 issue: 7 year: 2009 end-page: 3085 article-title: Chemokine expression in melanoma metastases associated with CD8+ T‐cell recruitment publication-title: Cancer Res – volume: 42 start-page: 768 issue: 6 year: 2006 end-page: 778 article-title: Cancer CXC chemokine networks and tumour angiogenesis publication-title: Eur J Cancer – volume: 5 issue: 10 year: 2016 article-title: Natural killer cell recognition of in vivo drug‐induced senescent multiple myeloma cells publication-title: Oncoimmunology – volume: 88 start-page: 1582 issue: 3 year: 2014 end-page: 1590 article-title: Direct, interferon‐independent activation of the CXCL10 promoter by NF‐kappaB and interferon regulatory factor 3 during hepatitis C virus infection publication-title: J Virol – volume: 515 start-page: 563 issue: 7528 year: 2014 end-page: 567 article-title: Predictive correlates of response to the anti‐PD‐L1 antibody MPDL3280A in cancer patients publication-title: Nature – volume: 60 start-page: 596 issue: 6 year: 2007 end-page: 599 article-title: CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors publication-title: J Clin Pathol – volume: 203 start-page: 2201 issue: 9 year: 2006 end-page: 2213 article-title: A novel chemokine receptor for SDF‐1 and I‐TAC involved in cell survival, cell adhesion, and tumor development publication-title: J Exp Med – volume: 14 start-page: R30 issue: 1 year: 2012 ident: 2023032108171750800_jlb10655-cit-0009 article-title: Modulation of CXCR3 ligand secretion by prostaglandin E2 and cyclooxygenase inhibitors in human breast cancer publication-title: Breast Cancer Res doi: 10.1186/bcr3115 – volume: 348 start-page: 203 issue: 3 year: 2003 ident: 2023032108171750800_jlb10655-cit-0035 article-title: Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer publication-title: N Engl J Med doi: 10.1056/NEJMoa020177 – volume: 106 start-page: 91 year: 2010 ident: 2023032108171750800_jlb10655-cit-0081 article-title: CXC chemokines in cancer angiogenesis and metastases publication-title: Adv Cancer Res doi: 10.1016/S0065-230X(10)06003-3 – volume: 11 start-page: 3 year: 2012 ident: 2023032108171750800_jlb10655-cit-0090 article-title: Altered CXCR3 isoform expression regulates prostate cancer cell migration and invasion publication-title: Mol Cancer doi: 10.1186/1476-4598-11-3 – volume: 46 start-page: 1872 issue: 12 year: 2015 ident: 2023032108171750800_jlb10655-cit-0113 article-title: Overexpression of the chemokine receptor CXCR3 and its correlation with favorable prognosis in gastric cancer publication-title: Hum Pathol doi: 10.1016/j.humpath.2015.08.004 – volume: 107 start-page: 628 issue: 2 year: 2010 ident: 2023032108171750800_jlb10655-cit-0132 article-title: Beta-arrestin- but not G protein-mediated signaling by the “decoy” receptor CXCR7 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.0912852107 – volume: 58 start-page: 2493 issue: 10 year: 2017 ident: 2023032108171750800_jlb10655-cit-0155 article-title: High expression levels of IP10/CXCL10 are associated with modulation of the natural killer cell compartment in multiple myeloma publication-title: Leuk Lymphoma doi: 10.1080/10428194.2017.1295144 – volume: 14 start-page: 12 year: 2014 ident: 2023032108171750800_jlb10655-cit-0134 article-title: Targeting CXCR4 with CTCE-9908 inhibits prostate tumor metastasis publication-title: BMC Urol doi: 10.1186/1471-2490-14-12 – volume: 197 start-page: 2016 issue: 5 year: 2016 ident: 2023032108171750800_jlb10655-cit-0058 article-title: Chemoattractant receptors BLT1 and CXCR3 regulate antitumor immunity by facilitating CD8+ T cell migration into tumors publication-title: J Immunol doi: 10.4049/jimmunol.1502376 – volume: 8 start-page: 14725 issue: 11 year: 2015 ident: 2023032108171750800_jlb10655-cit-0041 article-title: Impact of chemokine receptor CXCR3 on tumor-infiltrating lymphocyte recruitment associated with favorable prognosis in advanced gastric cancer publication-title: Int J Clin Exp Pathol – volume: 6 start-page: 7458 year: 2015 ident: 2023032108171750800_jlb10655-cit-0042 article-title: Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints publication-title: Nat Commun doi: 10.1038/ncomms8458 – volume: 59 start-page: 1401 issue: 9 year: 2010 ident: 2023032108171750800_jlb10655-cit-0061 article-title: Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN-alpha and IFN-gamma dependent manners publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-010-0876-3 – volume: 62 start-page: 2606 issue: 9 year: 2002 ident: 2023032108171750800_jlb10655-cit-0047 article-title: Immunotherapy with interleukin-10 depends on the CXC chemokines inducible protein-10 and monokine induced by IFN-gamma publication-title: Cancer Res – volume: 67 start-page: 3396 issue: 7 year: 2007 ident: 2023032108171750800_jlb10655-cit-0095 article-title: CXCL10 promotes invasion-related properties in human colorectal carcinoma cells publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-3087 – volume: 11 start-page: 597 issue: 9 year: 2011 ident: 2023032108171750800_jlb10655-cit-0083 article-title: Homeostatic chemokine receptors and organ-specific metastasis publication-title: Nat Rev Immunol doi: 10.1038/nri3049 – volume: 8 start-page: 755 issue: 10 year: 2008 ident: 2023032108171750800_jlb10655-cit-0122 article-title: Cancer stem cells in solid tumours: accumulating evidence and unresolved questions publication-title: Nat Rev Cancer doi: 10.1038/nrc2499 – volume: 307 start-page: 132 issue: 2 year: 2011 ident: 2023032108171750800_jlb10655-cit-0027 article-title: Chemokine receptor CXCR4-mediated transformation of mammary epithelial cells by enhancing multiple RTKs expression and deregulation of the p53/MDM2 axis publication-title: Cancer Lett doi: 10.1016/j.canlet.2011.03.025 – volume: 63 start-page: 40 year: 2018 ident: 2023032108171750800_jlb10655-cit-0022 article-title: CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2017.11.007 – volume: 30 start-page: 490 issue: 5 year: 2007 ident: 2023032108171750800_jlb10655-cit-0048 article-title: Immune-mediated modulation of breast cancer growth and metastasis by the chemokine Mig (CXCL9) in a murine model publication-title: J Immunother doi: 10.1097/CJI.0b013e318031b551 – volume: 268 start-page: 6677 issue: 9 year: 1993 ident: 2023032108171750800_jlb10655-cit-0003 article-title: Cooperative interaction between interferon (IFN) stimulus response element and kappa B sequence motifs controls IFN gamma- and lipopolysaccharide-stimulated transcription from the murine IP-10 promoter publication-title: J Biol Chem doi: 10.1016/S0021-9258(18)53303-2 – volume: 171 start-page: 2171 issue: 6 Pt 1 year: 2004 ident: 2023032108171750800_jlb10655-cit-0063 article-title: High expression of chemokine gene as a favorable prognostic factor in renal cell carcinoma publication-title: J Urol doi: 10.1097/01.ju.0000127726.25609.87 – volume: 107 issue: 10 year: 2015 ident: 2023032108171750800_jlb10655-cit-0023 article-title: Circulating inflammation markers, risk of lung cancer, and utility for risk stratification publication-title: J Natl Cancer Inst doi: 10.1093/jnci/djv199 – volume: 63 start-page: 141 issue: 1 year: 2016 ident: 2023032108171750800_jlb10655-cit-0129 article-title: Altered levels of plasma chemokines in breast cancer and their association with clinical and pathological characteristics publication-title: Neoplasma doi: 10.4149/neo_2016_017 – volume: 29 start-page: 709 issue: 4 year: 2010 ident: 2023032108171750800_jlb10655-cit-0123 article-title: CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression publication-title: Cancer Metastasis Rev doi: 10.1007/s10555-010-9256-x – volume: 190 start-page: 3696 issue: 7 year: 2013 ident: 2023032108171750800_jlb10655-cit-0143 article-title: CXCL9 causes heterologous desensitization of CXCL12-mediated memory T lymphocyte activation publication-title: J Immunol doi: 10.4049/jimmunol.1101293 – volume: 88 start-page: 1582 issue: 3 year: 2014 ident: 2023032108171750800_jlb10655-cit-0005 article-title: Direct, interferon-independent activation of the CXCL10 promoter by NF-kappaB and interferon regulatory factor 3 during hepatitis C virus infection publication-title: J Virol doi: 10.1128/JVI.02007-13 – volume: 7 start-page: 13976 issue: 12 year: 2016 ident: 2023032108171750800_jlb10655-cit-0020 article-title: Elevated expression of IFN-inducible CXCR3 ligands predicts poor prognosis in patients with non-metastatic clear-cell renal cell carcinoma publication-title: Oncotarget doi: 10.18632/oncotarget.7468 – volume: 232 start-page: 43 issue: 1 year: 2014 ident: 2023032108171750800_jlb10655-cit-0127 article-title: Cancer cell-derived lymphotoxin mediates reciprocal tumour-stromal interactions in human ovarian cancer by inducing CXCL11 in fibroblasts publication-title: J Pathol doi: 10.1002/path.4258 – volume: 18 start-page: 462 issue: 1 year: 2018 ident: 2023032108171750800_jlb10655-cit-0031 article-title: CXCL9/10/11, a regulator of PD-L1 expression in gastric cancer publication-title: BMC Cancer doi: 10.1186/s12885-018-4384-8 – volume: 69 start-page: 3077 issue: 7 year: 2009 ident: 2023032108171750800_jlb10655-cit-0002 article-title: Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-2281 – volume: 10 start-page: 942 issue: 9 year: 2004 ident: 2023032108171750800_jlb10655-cit-0074 article-title: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival publication-title: Nat Med doi: 10.1038/nm1093 – volume: 475 start-page: 226 issue: 7355 year: 2011 ident: 2023032108171750800_jlb10655-cit-0075 article-title: Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and T(reg) cells publication-title: Nature doi: 10.1038/nature10169 – volume: 54 start-page: 249 issue: 3 year: 2001 ident: 2023032108171750800_jlb10655-cit-0053 article-title: CD26: a multifunctional integral membrane and secreted protein of activated lymphocytes publication-title: Scand J Immunol doi: 10.1046/j.1365-3083.2001.00984.x – volume: 192 start-page: 567 issue: 2 year: 2014 ident: 2023032108171750800_jlb10655-cit-0092 article-title: The association of CXCR3 and renal cell carcinoma metastasis publication-title: J Urol doi: 10.1016/j.juro.2014.01.100 – volume: 127 start-page: 2300 issue: 10 year: 2010 ident: 2023032108171750800_jlb10655-cit-0103 article-title: Perivascular expression of CXCL9 and CXCL12 in primary central nervous system lymphoma: t-cell infiltration and positioning of malignant B cells publication-title: Int J Cancer doi: 10.1002/ijc.25236 – volume: 474 start-page: 609 issue: 7353 year: 2011 ident: 2023032108171750800_jlb10655-cit-0018 article-title: Integrated genomic analyses of ovarian carcinoma publication-title: Nature doi: 10.1038/nature10166 – volume: 33 start-page: 496 issue: 10 year: 2012 ident: 2023032108171750800_jlb10655-cit-0001 article-title: The pros and cons of chemokines in tumor immunology publication-title: Trends Immunol doi: 10.1016/j.it.2012.05.007 – volume: 5 start-page: e1218105 issue: 10 year: 2016 ident: 2023032108171750800_jlb10655-cit-0150 article-title: Natural killer cell recognition of in vivo drug-induced senescent multiple myeloma cells publication-title: Oncoimmunology doi: 10.1080/2162402X.2016.1218105 – volume: 10 start-page: e0128662 issue: 6 year: 2015 ident: 2023032108171750800_jlb10655-cit-0154 article-title: Lipopolysaccharide-induced CXCL10 mRNA level and six stimulant-mRNA combinations in whole blood: novel biomarkers for Bortezomib responses obtained from a prospective multicenter trial for patients with multiple myeloma publication-title: PLoS One doi: 10.1371/journal.pone.0128662 – volume: 71 start-page: 1214 issue: 4 year: 2011 ident: 2023032108171750800_jlb10655-cit-0137 article-title: Significance and mechanism of lymph node metastasis in cancer progression publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-10-3277 – volume: 276 start-page: 45098 issue: 48 year: 2001 ident: 2023032108171750800_jlb10655-cit-0085 article-title: Expression of functional chemokine receptors CXCR3 and CXCR4 on human melanoma cells publication-title: J Biol Chem doi: 10.1074/jbc.M106912200 – volume: 3 issue: S1 year: 2012 ident: 2023032108171750800_jlb10655-cit-0106 article-title: Cell trafficking in chronic lymphocytic leukemia publication-title: Open J Hematol doi: 10.13055/ojhmt_3_S1_03.120221 – volume: 176 start-page: 2581 issue: 4 year: 2006 ident: 2023032108171750800_jlb10655-cit-0119 article-title: Epithelial CXCR3-B regulates chemokines bioavailability in normal, but not in Sjogren’s syndrome, salivary glands publication-title: J Immunol doi: 10.4049/jimmunol.176.4.2581 – volume: 371 start-page: 162 issue: 1 year: 2018 ident: 2023032108171750800_jlb10655-cit-0136 article-title: CXCR3 expression in colorectal cancer cells enhanced invasion through preventing CXCR4 internalization publication-title: Exp Cell Res doi: 10.1016/j.yexcr.2018.08.006 – volume: 109 start-page: 4598 issue: 12 year: 2012 ident: 2023032108171750800_jlb10655-cit-0142 article-title: Chemokine receptor CXCR3 agonist prevents human T-cell migration in a humanized model of arthritic inflammation publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1118104109 – volume: 5 start-page: 11064 issue: 22 year: 2014 ident: 2023032108171750800_jlb10655-cit-0019 article-title: IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival publication-title: Oncotarget doi: 10.18632/oncotarget.2519 – volume: 168 start-page: 1662 issue: 7 year: 2013 ident: 2023032108171750800_jlb10655-cit-0141 article-title: Identification and profiling of CXCR3-CXCR4 chemokine receptor heteromer complexes publication-title: Br J Pharmacol doi: 10.1111/bph.12064 – volume: 124 start-page: 2009 issue: 5 year: 2014 ident: 2023032108171750800_jlb10655-cit-0159 article-title: CXCL11-dependent induction of FOXP3-negative regulatory T cells suppresses autoimmune encephalomyelitis publication-title: J Clin Invest doi: 10.1172/JCI71951 – volume: 86 start-page: 902 issue: 9 year: 2006 ident: 2023032108171750800_jlb10655-cit-0007 article-title: TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis publication-title: Lab Invest doi: 10.1038/labinvest.3700453 – volume: 9 start-page: 4308 issue: 9 year: 2017 ident: 2023032108171750800_jlb10655-cit-0072 article-title: MiR-15a-5p negatively regulates cell survival and metastasis by targeting CXCL10 in chronic myeloid leukemia publication-title: Am J Transl Res – volume: 103 start-page: 258 issue: 2 year: 2005 ident: 2023032108171750800_jlb10655-cit-0030 article-title: Up-regulation of the interferon gamma (IFN-gamma)-inducible chemokines IFN-inducible T-cell alpha chemoattractant and monokine induced by IFN-gamma and of their receptor CXC receptor 3 in human renal cell carcinoma publication-title: Cancer doi: 10.1002/cncr.20747 – volume: 114 start-page: 896 issue: 6 year: 2005 ident: 2023032108171750800_jlb10655-cit-0102 article-title: CXCR3-positive B cells found at elevated frequency in the peripheral blood of patients with MALT lymphoma are attracted by MIG and belong to the lymphoma clone publication-title: Int J Cancer doi: 10.1002/ijc.20823 – volume: 2 start-page: 583 issue: 4 year: 2011 ident: 2023032108171750800_jlb10655-cit-0073 article-title: The emerging role of CXCL10 in cancer (Review) publication-title: Oncol Lett doi: 10.3892/ol.2011.300 – volume: 26 start-page: 1997 year: 2020 ident: 2023032108171750800_jlb10655-cit-0021 article-title: A four-chemokine signature is associated with a T-cell-inflamed phenotype in primary and metastatic pancreatic cancer publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-19-2803 – volume: 184 start-page: 963 issue: 3 year: 1996 ident: 2023032108171750800_jlb10655-cit-0108 article-title: Chemokine receptor specific for IP10 and mig: structure, function, and expression in activated T-lymphocytes publication-title: J Exp Med doi: 10.1084/jem.184.3.963 – volume: 2 start-page: 240 year: 2011 ident: 2023032108171750800_jlb10655-cit-0104 article-title: Inflammation driven by tumour-specific Th1 cells protects against B-cell cancer publication-title: Nat Commun doi: 10.1038/ncomms1239 – volume: 184 start-page: 1566 issue: 3 year: 2010 ident: 2023032108171750800_jlb10655-cit-0008 article-title: Regulation of lentivirus neurovirulence by lipopolysaccharide conditioning: suppression of CXCL10 in the brain by IL-10 publication-title: J Immunol doi: 10.4049/jimmunol.0902575 – volume: 17 start-page: 929 issue: 4 year: 2010 ident: 2023032108171750800_jlb10655-cit-0025 article-title: The chemokine CXCL1 induces proliferation in epithelial ovarian cancer cells by transactivation of the epidermal growth factor receptor publication-title: Endocr Relat Cancer doi: 10.1677/ERC-10-0107 – volume: 66 start-page: 7701 issue: 15 year: 2006 ident: 2023032108171750800_jlb10655-cit-0038 article-title: Antagonism of CXCR3 inhibits lung metastasis in a murine model of metastatic breast cancer publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-06-0709 – volume: 8 start-page: 490 issue: 3 year: 2009 ident: 2023032108171750800_jlb10655-cit-0089 article-title: CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model publication-title: Mol Cancer Ther doi: 10.1158/1535-7163.MCT-08-0485 – volume: 72 start-page: 5209 issue: 20 year: 2012 ident: 2023032108171750800_jlb10655-cit-0057 article-title: PD-1 blockade enhances T-cell migration to tumors by elevating IFN-gamma inducible chemokines publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-12-1187 – volume: 7 start-page: 14405 issue: 12 year: 2016 ident: 2023032108171750800_jlb10655-cit-0093 article-title: An alternatively spliced variant of CXCR3 mediates the metastasis of CD133+ liver cancer cells induced by CXCL9 publication-title: Oncotarget doi: 10.18632/oncotarget.7360 – volume: 64 start-page: 225 issue: 2 year: 2015 ident: 2023032108171750800_jlb10655-cit-0014 article-title: CXCL10-induced migration of adoptively transferred human natural killer cells toward solid tumors causes regression of tumor growth in vivo publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-014-1629-5 – volume: 207 start-page: 221 issue: 2 year: 2004 ident: 2023032108171750800_jlb10655-cit-0115 article-title: CXCR3-binding chemokines in multiple myeloma publication-title: Cancer Lett doi: 10.1016/j.canlet.2003.10.036 – volume: 12 start-page: 298 issue: 4 year: 2012 ident: 2023032108171750800_jlb10655-cit-0037 article-title: The immune contexture in human tumours: impact on clinical outcome publication-title: Nat Rev Cancer doi: 10.1038/nrc3245 – volume: 449 start-page: 163 year: 2019 ident: 2023032108171750800_jlb10655-cit-0032 article-title: CXCL11 promotes self-renewal and tumorigenicity of alpha2delta1(+) liver tumor-initiating cells through CXCR3/ERK1/2 signaling publication-title: Cancer Lett doi: 10.1016/j.canlet.2019.02.016 – volume: 439 start-page: 384 issue: 3 year: 2013 ident: 2023032108171750800_jlb10655-cit-0070 article-title: miRNA-21 inhibition enhances RANTES and IP-10 release in MCF-7 via PIAS3 and STAT3 signalling and causes increased lymphocyte migration publication-title: Biochem Biophys Res Commun doi: 10.1016/j.bbrc.2013.08.072 – volume: 190 start-page: 372 issue: 1 year: 2013 ident: 2023032108171750800_jlb10655-cit-0010 article-title: AMP-activated protein kinase restricts IFN-gamma signaling publication-title: J Immunol doi: 10.4049/jimmunol.1202390 – volume: 95 start-page: 627 issue: 2 year: 2000 ident: 2023032108171750800_jlb10655-cit-0084 article-title: The chemokine receptor CXCR3 is expressed in a subset of B-cell lymphomas and is a marker of B-cell chronic lymphocytic leukemia publication-title: Blood doi: 10.1182/blood.V95.2.627 – volume: 5 start-page: 271 year: 2018 ident: 2023032108171750800_jlb10655-cit-0118 article-title: The role of CXCR3 and its chemokine ligands in skin disease and cancer publication-title: Front Med (Lausanne) doi: 10.3389/fmed.2018.00271 – volume: 190 start-page: 832 issue: 2 year: 2013 ident: 2023032108171750800_jlb10655-cit-0064 article-title: Cutaneous tumors cease CXCL9/Mig production as a result of IFN-gamma-mediated immunoediting publication-title: J Immunol doi: 10.4049/jimmunol.1201906 – volume: 72 start-page: 4351 issue: 17 year: 2012 ident: 2023032108171750800_jlb10655-cit-0033 article-title: CXCR3+ T regulatory cells selectively accumulate in human ovarian carcinomas to limit type I immunity publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-12-0579 – volume: 42 start-page: 768 issue: 6 year: 2006 ident: 2023032108171750800_jlb10655-cit-0044 article-title: Cancer CXC chemokine networks and tumour angiogenesis publication-title: Eur J Cancer doi: 10.1016/j.ejca.2006.01.006 – volume: 7 start-page: 115 issue: 1 year: 2019 ident: 2023032108171750800_jlb10655-cit-0055 article-title: Dipeptidyl peptidase 4 inhibitors reduce hepatocellular carcinoma by activating lymphocyte chemotaxis in mice publication-title: Cell Mol Gastroenterol Hepatol doi: 10.1016/j.jcmgh.2018.08.008 – volume: 206 start-page: 68 issue: 1 year: 2005 ident: 2023032108171750800_jlb10655-cit-0013 article-title: Expression of the interferon-inducible chemokine IP-10 (CXCL10), a chemokine with proposed anti-neoplastic functions, in Hodgkin lymphoma and nasopharyngeal carcinoma publication-title: J Pathol doi: 10.1002/path.1745 – volume: 111 start-page: 3155 issue: 6 year: 2008 ident: 2023032108171750800_jlb10655-cit-0147 article-title: Autologous antitumor activity by NK cells expanded from myeloma patients using GMP-compliant components publication-title: Blood doi: 10.1182/blood-2007-09-110312 – volume: 285 start-page: 36842 issue: 47 year: 2010 ident: 2023032108171750800_jlb10655-cit-0112 article-title: CXCR3-B can mediate growth-inhibitory signals in human renal cancer cells by down-regulating the expression of heme oxygenase-1 publication-title: J Biol Chem doi: 10.1074/jbc.M110.170324 – volume: 20 issue: 11 year: 2019 ident: 2023032108171750800_jlb10655-cit-0065 article-title: Hyperprogression under immunotherapy publication-title: Int J Mol Sci doi: 10.3390/ijms20112674 – volume: 55 start-page: 1320 issue: 11 year: 2006 ident: 2023032108171750800_jlb10655-cit-0087 article-title: Expression of macrophage-derived chemokine (MDC)/CCL22 in human lung cancer publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-006-0133-y – volume: 40 start-page: 1764 issue: 9 year: 2008 ident: 2023032108171750800_jlb10655-cit-0111 article-title: Activation of p38(MAPK) mediates the angiostatic effect of the chemokine receptor CXCR3-B publication-title: Int J Biochem Cell Biol doi: 10.1016/j.biocel.2008.01.008 – volume: 30 start-page: 417 issue: 4 year: 2007 ident: 2023032108171750800_jlb10655-cit-0161 article-title: Expression of CXCR3 on mononuclear cells and CXCR3 ligands in patients with metastatic renal cell carcinoma in response to systemic IL-2 therapy publication-title: J Immunother doi: 10.1097/CJI.0b013e31802e089a – volume: 5 start-page: e1250051 issue: 12 year: 2016 ident: 2023032108171750800_jlb10655-cit-0149 article-title: Novel treatment strategy with autologous activated and expanded natural killer cells plus anti-myeloma drugs for multiple myeloma publication-title: Oncoimmunology doi: 10.1080/2162402X.2016.1250051 – volume: 138 start-page: 1429 issue: 4 year: 2010 ident: 2023032108171750800_jlb10655-cit-0043 article-title: Biomolecular network reconstruction identifies T-cell homing factors associated with survival in colorectal cancer publication-title: Gastroenterology doi: 10.1053/j.gastro.2009.10.057 – volume: 8 start-page: 1970 year: 2017 ident: 2023032108171750800_jlb10655-cit-0052 article-title: Overview of the mechanisms that may contribute to the non-redundant activities of interferon-inducible CXC chemokine receptor 3 ligands publication-title: Front Immunol doi: 10.3389/fimmu.2017.01970 – volume: 5 start-page: e1074374 issue: 2 year: 2016 ident: 2023032108171750800_jlb10655-cit-0160 article-title: Hydrogel dual delivered celecoxib and anti-PD-1 synergistically improve antitumor immunity publication-title: Oncoimmunology doi: 10.1080/2162402X.2015.1074374 – volume: 272 start-page: 14899 issue: 23 year: 1997 ident: 2023032108171750800_jlb10655-cit-0004 article-title: Synergy between interferon-gamma and tumor necrosis factor-alpha in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and nuclear factor kappaB publication-title: J Biol Chem doi: 10.1074/jbc.272.23.14899 – volume: 92 start-page: 171 issue: 1-2 year: 2004 ident: 2023032108171750800_jlb10655-cit-0086 article-title: The expression of the chemokine receptor CXCR3 and its ligand, CXCL10, in human breast adenocarcinoma cell lines publication-title: Immunol Lett doi: 10.1016/j.imlet.2003.10.020 – volume: 113 start-page: 6085 issue: 24 year: 2009 ident: 2023032108171750800_jlb10655-cit-0130 article-title: CXCR7 heterodimerizes with CXCR4 and regulates CXCL12-mediated G protein signaling publication-title: Blood doi: 10.1182/blood-2008-12-196618 – volume: 70 start-page: 255 year: 2018 ident: 2023032108171750800_jlb10655-cit-0151 article-title: Translating the anti-myeloma activity of natural killer cells into clinical application publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2018.10.005 – volume: 9 start-page: 646 issue: 5 year: 2019 ident: 2023032108171750800_jlb10655-cit-0006 article-title: Targeting DNA damage response promotes antitumor immunity through STING-mediated T-cell activation in small cell lung cancer publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-18-1020 – volume: 82 start-page: 500 issue: 8 year: 2003 ident: 2023032108171750800_jlb10655-cit-0140 article-title: CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease publication-title: Ann Hematol doi: 10.1007/s00277-003-0679-0 – volume: 21 start-page: 1191 issue: 4 year: 2015 ident: 2023032108171750800_jlb10655-cit-0128 article-title: Expression of the chemokine receptors CXCR3, CXCR4, CXCR7 and their ligands in rhabdomyosarcoma publication-title: Pathol Oncol Res doi: 10.1007/s12253-015-9947-2 – volume: 35 start-page: 885 issue: 6 year: 2019 ident: 2023032108171750800_jlb10655-cit-0017 article-title: Cooperation between constitutive and inducible chemokines enables T cell engraftment and immune attack in solid tumors publication-title: Cancer Cell doi: 10.1016/j.ccell.2019.05.004 – volume: 110 start-page: 37 issue: 1 year: 2007 ident: 2023032108171750800_jlb10655-cit-0051 article-title: Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration publication-title: Blood doi: 10.1182/blood-2006-10-049072 – volume: 129 start-page: 5518 issue: 12 year: 2019 ident: 2023032108171750800_jlb10655-cit-0071 article-title: Suppressing miR-21 activity in tumor-associated macrophages promotes an antitumor immune response publication-title: J Clin Invest doi: 10.1172/JCI127125 – volume: 100 start-page: 1755 issue: 11 year: 2009 ident: 2023032108171750800_jlb10655-cit-0101 article-title: Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism publication-title: Br J Cancer doi: 10.1038/sj.bjc.6605078 – volume: 31 start-page: 4750 issue: 45 year: 2012 ident: 2023032108171750800_jlb10655-cit-0131 article-title: Scavenging of CXCL12 by CXCR7 promotes tumor growth and metastasis of CXCR4-positive breast cancer cells publication-title: Oncogene doi: 10.1038/onc.2011.633 – volume: 68 start-page: 8437 issue: 20 year: 2008 ident: 2023032108171750800_jlb10655-cit-0039 article-title: Natural killer cell accumulation in tumors is dependent on IFN-gamma and CXCR3 ligands publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-08-1440 – volume: 89 start-page: 85 issue: 1 year: 2011 ident: 2023032108171750800_jlb10655-cit-0125 article-title: Foxp3+IL-17+ T cells promote development of cancer-initiating cells in colorectal cancer publication-title: J Leukoc Biol doi: 10.1189/jlb.0910506 – volume: 527 start-page: 249 issue: 7577 year: 2015 ident: 2023032108171750800_jlb10655-cit-0067 article-title: Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy publication-title: Nature doi: 10.1038/nature15520 – volume: 91 start-page: 1489 issue: 11 year: 2006 ident: 2023032108171750800_jlb10655-cit-0152 article-title: CXCR3 and its binding chemokines in myeloma cells: expression of isoforms and potential relationships with myeloma cell proliferation and survival publication-title: Haematologica – volume: 19 start-page: 336 issue: 2 year: 2013 ident: 2023032108171750800_jlb10655-cit-0024 article-title: Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-11-3314 – volume: 104 start-page: 469 issue: 3 year: 2011 ident: 2023032108171750800_jlb10655-cit-0097 article-title: CXCL9 induces chemotaxis, chemorepulsion and endothelial barrier disruption through CXCR3-mediated activation of melanoma cells publication-title: Br J Cancer doi: 10.1038/sj.bjc.6606056 – volume: 90 start-page: 483 issue: 4 year: 2016 ident: 2023032108171750800_jlb10655-cit-0107 article-title: CXC chemokine receptor 3 alternative splice variants selectively activate different signaling pathways publication-title: Mol Pharmacol doi: 10.1124/mol.116.105502 – volume: 30 start-page: 781 issue: 7 year: 2015 ident: 2023032108171750800_jlb10655-cit-0109 article-title: CXCR3 in carcinoma progression publication-title: Histol Histopathol – volume: 66 start-page: 373 issue: 5 year: 2012 ident: 2023032108171750800_jlb10655-cit-0091 article-title: The prognostic significance of chemokine receptor CXCR3 expression in colorectal carcinoma publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2011.12.003 – volume: 48 start-page: 169 year: 2019 ident: 2023032108171750800_jlb10655-cit-0066 article-title: Role of CXCR3 signaling in response to anti-PD-1 therapy publication-title: EBioMedicine doi: 10.1016/j.ebiom.2019.08.067 – volume: 204 start-page: 345 issue: 2 year: 2007 ident: 2023032108171750800_jlb10655-cit-0045 article-title: In vivo imaging of cytotoxic T cell infiltration and elimination of a solid tumor publication-title: J Exp Med doi: 10.1084/jem.20061890 – volume: 179 start-page: 4272 issue: 6 year: 2007 ident: 2023032108171750800_jlb10655-cit-0105 article-title: Down-modulation of CXCR3 surface expression and function in CD8+ T cells from cutaneous T cell lymphoma patients publication-title: J Immunol doi: 10.4049/jimmunol.179.6.4272 – volume: 4 start-page: 12 year: 2013 ident: 2023032108171750800_jlb10655-cit-0156 article-title: Differential chemotactic receptor requirements for NK cell subset trafficking into bone marrow publication-title: Front Immunol doi: 10.3389/fimmu.2013.00012 – volume: 7 start-page: e33747 issue: 5 year: 2012 ident: 2023032108171750800_jlb10655-cit-0028 article-title: Deficiency of C-C chemokine receptor 5 suppresses tumor development via inactivation of NF-kappaB and upregulation of IL-1Ra in melanoma model publication-title: PLoS One doi: 10.1371/journal.pone.0033747 – volume: 101 start-page: e99 issue: 3 year: 2016 ident: 2023032108171750800_jlb10655-cit-0139 article-title: Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors publication-title: Haematologica doi: 10.3324/haematol.2015.133470 – volume: 20 start-page: 2020 issue: 11 year: 2016 ident: 2023032108171750800_jlb10655-cit-0094 article-title: TNF-alpha augments CXCR2 and CXCR3 to promote progression of renal cell carcinoma publication-title: J Cell Mol Med doi: 10.1111/jcmm.12890 – volume: 132 start-page: 503 issue: 4 year: 2011 ident: 2023032108171750800_jlb10655-cit-0117 article-title: Expression and agonist responsiveness of CXCR3 variants in human T lymphocytes publication-title: Immunology doi: 10.1111/j.1365-2567.2010.03384.x – volume: 173 start-page: 6234 issue: 10 year: 2004 ident: 2023032108171750800_jlb10655-cit-0116 article-title: Identification and partial characterization of a variant of human CXCR3 generated by posttranscriptional exon skipping publication-title: J Immunol doi: 10.4049/jimmunol.173.10.6234 – volume: 116 start-page: 949 issue: 6 year: 2005 ident: 2023032108171750800_jlb10655-cit-0099 article-title: Selective infiltration of CCR5(+)CXCR3(+) T lymphocytes in human colorectal carcinoma publication-title: Int J Cancer doi: 10.1002/ijc.21135 – volume: 515 start-page: 563 issue: 7528 year: 2014 ident: 2023032108171750800_jlb10655-cit-0056 article-title: Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients publication-title: Nature doi: 10.1038/nature14011 – volume: 313 start-page: 1960 issue: 5795 year: 2006 ident: 2023032108171750800_jlb10655-cit-0034 article-title: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome publication-title: Science doi: 10.1126/science.1129139 – volume: 7 start-page: 290 issue: 1 year: 2019 ident: 2023032108171750800_jlb10655-cit-0158 article-title: Targeting of CXCR3 improves anti-myeloma efficacy of adoptively transferred activated natural killer cells publication-title: J Immunother Cancer doi: 10.1186/s40425-019-0751-5 – volume: 164 start-page: 3112 issue: 6 year: 2000 ident: 2023032108171750800_jlb10655-cit-0046 article-title: Intratumoral coinjection of two adenoviruses, one encoding the chemokine IFN-gamma-inducible protein-10 and another encoding IL-12, results in marked antitumoral synergy publication-title: J Immunol doi: 10.4049/jimmunol.164.6.3112 – volume: 64 start-page: 7697 issue: 21 year: 2004 ident: 2023032108171750800_jlb10655-cit-0040 article-title: CXC chemokine receptor 3 expression by activated CD8+ T cells is associated with survival in melanoma patients with stage III disease publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-04-2059 – volume: 4 start-page: 540 issue: 7 year: 2004 ident: 2023032108171750800_jlb10655-cit-0079 article-title: Cancer and the chemokine network publication-title: Nat Rev Cancer doi: 10.1038/nrc1388 – volume: 50 start-page: 1498 issue: 6 year: 2019 ident: 2023032108171750800_jlb10655-cit-0059 article-title: Intratumoral activity of the CXCR3 chemokine system is required for the efficacy of anti-PD-1 therapy publication-title: Immunity doi: 10.1016/j.immuni.2019.04.010 – volume: 3 start-page: 956 issue: 8 year: 2015 ident: 2023032108171750800_jlb10655-cit-0069 article-title: Melanoma induces, and adenosine suppresses, CXCR3-cognate chemokine production and T-cell infiltration of lungs bearing metastatic-like disease publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-15-0015 – volume: 58 start-page: 599 issue: 3 year: 2012 ident: 2023032108171750800_jlb10655-cit-0126 article-title: Candidate serum biomarkers for prostate adenocarcinoma identified by mRNA differences in prostate tissue and verified with protein measurements in tissue and blood publication-title: Clin Chem doi: 10.1373/clinchem.2011.171637 – volume: 86 start-page: 1221 issue: 12 year: 2006 ident: 2023032108171750800_jlb10655-cit-0135 article-title: Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion publication-title: Lab Invest doi: 10.1038/labinvest.3700482 – volume: 26 start-page: 192 issue: 1 year: 2019 ident: 2023032108171750800_jlb10655-cit-0011 article-title: Genetic liver-specific AMPK activation protects against diet-induced obesity and NAFLD publication-title: Cell Rep doi: 10.1016/j.celrep.2018.12.036 – volume: 29 start-page: 235 year: 2011 ident: 2023032108171750800_jlb10655-cit-0076 article-title: Natural innate and adaptive immunity to cancer publication-title: Annu Rev Immunol doi: 10.1146/annurev-immunol-031210-101324 – volume: 198 start-page: 2115 issue: 5 year: 2017 ident: 2023032108171750800_jlb10655-cit-0157 article-title: CXCR3/CXCL10 Axis Regulates Neutrophil-NK cell cross-talk determining the severity of experimental osteoarthritis publication-title: J Immunol doi: 10.4049/jimmunol.1601359 – volume: 6 start-page: 43408 issue: 41 year: 2015 ident: 2023032108171750800_jlb10655-cit-0096 article-title: CXCR3 as a molecular target in breast cancer metastasis: inhibition of tumor cell migration and promotion of host anti-tumor immunity publication-title: Oncotarget doi: 10.18632/oncotarget.6125 – volume: 16 start-page: R54 issue: 3 year: 2014 ident: 2023032108171750800_jlb10655-cit-0026 article-title: C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment publication-title: Breast Cancer Res doi: 10.1186/bcr3665 – volume: 16 start-page: 850 issue: 8 year: 2015 ident: 2023032108171750800_jlb10655-cit-0054 article-title: Dipeptidylpeptidase 4 inhibition enhances lymphocyte trafficking, improving both naturally occurring tumor immunity and immunotherapy publication-title: Nat Immunol doi: 10.1038/ni.3201 – volume: 71 start-page: 6997 issue: 22 year: 2011 ident: 2023032108171750800_jlb10655-cit-0049 article-title: Chemotherapy induces intratumoral expression of chemokines in cutaneous melanoma, favoring T-cell infiltration and tumor control publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-11-1466 – volume: 119 start-page: 660 issue: 3 year: 2002 ident: 2023032108171750800_jlb10655-cit-0146 article-title: Anti-myeloma activity of natural killer lymphocytes publication-title: Br J Haematol doi: 10.1046/j.1365-2141.2002.03879.x – volume: 188 start-page: 198 issue: 1 year: 2012 ident: 2023032108171750800_jlb10655-cit-0068 article-title: Adenosine A2B receptor blockade slows growth of bladder and breast tumors publication-title: J Immunol doi: 10.4049/jimmunol.1101845 – volume: 113 start-page: 327 issue: 2 year: 2015 ident: 2023032108171750800_jlb10655-cit-0100 article-title: Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome publication-title: Br J Cancer doi: 10.1038/bjc.2015.193 – volume: 24 start-page: 6447 issue: 24 year: 2018 ident: 2023032108171750800_jlb10655-cit-0015 article-title: IFNgamma-induced chemokines are required for CXCR3-mediated T-Cell recruitment and antitumor efficacy of anti-HER2/CD3 bispecific antibody publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-18-1139 – volume: 25 start-page: 201 issue: 4 year: 2004 ident: 2023032108171750800_jlb10655-cit-0016 article-title: CXC chemokines: the regulatory link between inflammation and angiogenesis publication-title: Trends Immunol doi: 10.1016/j.it.2004.02.006 – volume: 197 start-page: 1537 issue: 11 year: 2003 ident: 2023032108171750800_jlb10655-cit-0114 article-title: An alternatively spliced variant of CXCR3 mediates the inhibition of endothelial cell growth induced by IP-10, Mig, and I-TAC, and acts as functional receptor for platelet factor 4 publication-title: J Exp Med doi: 10.1084/jem.20021897 – volume: 75 start-page: 4766 issue: 22 year: 2015 ident: 2023032108171750800_jlb10655-cit-0144 article-title: Multiple myeloma impairs bone marrow localization of effector natural killer cells by altering the chemokine microenvironment publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-15-1320 – volume: 5 start-page: 90 issue: 1 year: 2017 ident: 2023032108171750800_jlb10655-cit-0060 article-title: Prospects for combined use of oncolytic viruses and CAR T-cells publication-title: J Immunother Cancer doi: 10.1186/s40425-017-0294-6 – volume: 7 start-page: 45593 year: 2017 ident: 2023032108171750800_jlb10655-cit-0077 article-title: CXCR3(+) monocytes/macrophages are required for establishment of pulmonary metastases publication-title: Sci Rep doi: 10.1038/srep45593 – volume: 2 start-page: e26663 issue: 12 year: 2013 ident: 2023032108171750800_jlb10655-cit-0148 article-title: Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma publication-title: Oncoimmunology doi: 10.4161/onci.26663 – volume: 267 start-page: 226 issue: 2 year: 2008 ident: 2023032108171750800_jlb10655-cit-0082 article-title: The role of CXC chemokines and their receptors in cancer publication-title: Cancer Lett doi: 10.1016/j.canlet.2008.04.050 – volume: 8 start-page: 30383 issue: 18 year: 2017 ident: 2023032108171750800_jlb10655-cit-0145 article-title: Neoplastic plasma cells generate an inflammatory environment within bone marrow and markedly alter the distribution of T cells between lymphoid compartments publication-title: Oncotarget doi: 10.18632/oncotarget.16628 – volume: 357 start-page: 539 issue: 9255 year: 2001 ident: 2023032108171750800_jlb10655-cit-0078 article-title: Inflammation and cancer: back to Virchow? publication-title: Lancet doi: 10.1016/S0140-6736(00)04046-0 – volume: 25 start-page: 345 issue: 4 year: 2008 ident: 2023032108171750800_jlb10655-cit-0080 article-title: Organ selectivity in metastasis: regulation by chemokines and their receptors publication-title: Clin Exp Metastasis doi: 10.1007/s10585-007-9097-3 – volume: 410 start-page: 50 issue: 6824 year: 2001 ident: 2023032108171750800_jlb10655-cit-0120 article-title: Involvement of chemokine receptors in breast cancer metastasis publication-title: Nature doi: 10.1038/35065016 – volume: 178 start-page: 1057 issue: 3 year: 1993 ident: 2023032108171750800_jlb10655-cit-0012 article-title: IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo publication-title: J Exp Med doi: 10.1084/jem.178.3.1057 – volume: 64 start-page: 4010 issue: 11 year: 2004 ident: 2023032108171750800_jlb10655-cit-0029 article-title: Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-03-1757 – volume: 60 start-page: 596 issue: 6 year: 2007 ident: 2023032108171750800_jlb10655-cit-0098 article-title: CXCR3 chemokine receptor immunoreactivity in primary cutaneous malignant melanoma: correlation with clinicopathological prognostic factors publication-title: J Clin Pathol doi: 10.1136/jcp.2005.032144 – volume: 24 start-page: 41 issue: 1 year: 2013 ident: 2023032108171750800_jlb10655-cit-0133 article-title: Chemokine receptor trio: cXCR3, CXCR4 and CXCR7 crosstalk via CXCL11 and CXCL12 publication-title: Cytokine Growth Factor Rev doi: 10.1016/j.cytogfr.2012.08.007 – volume: 60 start-page: 497 issue: 7 year: 2010 ident: 2023032108171750800_jlb10655-cit-0124 article-title: CXCR4 and cancer publication-title: Pathol Int doi: 10.1111/j.1440-1827.2010.02548.x – volume: 391 start-page: 2128 issue: 10135 year: 2018 ident: 2023032108171750800_jlb10655-cit-0036 article-title: International validation of the consensus immunoscore for the classification of colon cancer: a prognostic and accuracy study publication-title: Lancet doi: 10.1016/S0140-6736(18)30789-X – volume: 57 start-page: 2516 issue: 11 year: 2016 ident: 2023032108171750800_jlb10655-cit-0153 article-title: Monokine induced by interferon gamma (MIG/CXCL9) is an independent prognostic factor in newly diagnosed myeloma publication-title: Leuk Lymphoma doi: 10.3109/10428194.2016.1151511 – volume: 26 start-page: 4679 issue: 32 year: 2007 ident: 2023032108171750800_jlb10655-cit-0088 article-title: Chemokine receptor CXCR3 promotes colon cancer metastasis to lymph nodes publication-title: Oncogene doi: 10.1038/sj.onc.1210267 – volume: 170 start-page: 1109 issue: 6 year: 2017 ident: 2023032108171750800_jlb10655-cit-0062 article-title: Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti-PD-1 immunotherapy publication-title: Cell doi: 10.1016/j.cell.2017.08.027 – volume: 19 start-page: S339 issue: Suppl 3 year: 2012 ident: 2023032108171750800_jlb10655-cit-0138 article-title: CXCR4 expression predicts patient outcome and recurrence patterns after hepatic resection for colorectal liver metastases publication-title: Ann Surg Oncol doi: 10.1245/s10434-011-1774-4 – volume: 199 start-page: 35 issue: 1-2 year: 2008 ident: 2023032108171750800_jlb10655-cit-0110 article-title: Chemokine production and chemokine receptor expression by human glioma cells: role of CXCL10 in tumour cell proliferation publication-title: J Neuroimmunol doi: 10.1016/j.jneuroim.2008.04.029 – volume: 203 start-page: 2201 issue: 9 year: 2006 ident: 2023032108171750800_jlb10655-cit-0121 article-title: A novel chemokine receptor for SDF-1 and I-TAC involved in cell survival, cell adhesion, and tumor development publication-title: J Exp Med doi: 10.1084/jem.20052144 – volume: 20 start-page: 1301 issue: 11 year: 2014 ident: 2023032108171750800_jlb10655-cit-0050 article-title: Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy publication-title: Nat Med doi: 10.1038/nm.3708
SSID	ssj0003260
Score	2.4888268
SecondaryResourceType	review_article
Snippet	Tumor tissue includes cancer cells and normal stromal cells such as vascular endothelial cells, connective tissue cells (cancer associated fibroblast,...
SourceID	proquest pubmed crossref wiley
SourceType	Aggregation Database Index Database Enrichment Source Publisher
StartPage	673
SubjectTerms	Animals anti‐tumor immunity Biomarkers Cancer cancer immunotherapy CD8 antigen Cell activation Cell survival Cell Transformation, Neoplastic - genetics Cell Transformation, Neoplastic - metabolism Chemokines Connective tissues CXCL10 CXCL10 protein CXCL11 protein CXCR3 protein Dendritic cells Disease Susceptibility Endothelial cells Eosinophils Gene Duplication Gene Expression Regulation, Neoplastic Homeostasis Humans Immune response immune suppression Immune system Immunomodulation Immunotherapy Inflammation Leukocytes (basophilic) Leukocytes (eosinophilic) Ligands lymphocyte migration Lymphocytes Lymphocytes T Macrophages Mast cells Mesenchymal stem cells Metastases Molecular modelling Natural killer cells Neoplasms - etiology Neoplasms - metabolism Neoplasms - pathology Protein Binding Receptors, CXCR3 - genetics Receptors, CXCR3 - metabolism Signal Transduction Solid tumors Stem cells Stromal cells Tumors
Title	Tumor inhibition or tumor promotion? The duplicity of CXCR3 in cancer
URI	https://onlinelibrary.wiley.com/doi/abs/10.1002%2FJLB.5MR0320-205R https://www.ncbi.nlm.nih.gov/pubmed/32745326 https://www.proquest.com/docview/3248791683 https://www.proquest.com/docview/2430374369
Volume	108
WOSCitedRecordID	wos000554805200020&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVWIB databaseName: Wiley Online Library Full Collection 2020 customDbUrl: eissn: 1938-3673 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0003260 issn: 0741-5400 databaseCode: DRFUL dateStart: 19970101 isFulltext: true titleUrlDefault: https://onlinelibrary.wiley.com providerName: Wiley-Blackwell
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bS8MwFD54BV-8zNt0jggi-FC3Nk3bPep0iEwfxoS9laQXHGgnuwj-e780td5AEXxs2qTh3PKd5OQcoiMhAh7HLddSzTi1XFdJS8aetJo8kYFS8OV8U2zCv70NBoPWx7swJj9EueGmNSO311rBpZo03pOGXnfPT8VNTxcAB6tFb54W9d0qOGCLF73OXbe0xwAoTZOM09ZhAM3isBKjNL6O8Xlx-oY4PwPYfAXqrP3H3NdptcCf7MwIzAbNJVmFNs8y-N6PL-yY5RGh-VZ7hZZNocqXTbrszx5HYzbM7ocqj_FieJrmbU8mng-onUHkWDzTB-KA9myUsvag3ePoxSItW-Mt6ncu--0rqyjAYEUugJyV2qkXO4IrBZSmhOBeBEAQpLYjwfjAhZ2ELeXwqGAHIlsqKLOTuH6cAnRwm2_TQjbKkl1iGrZ4ArxP4ZBiiJbnK19FNpZo4CPpVqnxRvgwKpKT6xoZD6FJq-yEIFlYkCzUJKvSSdnjySTm-OHb2hsvw0JFJyGQZOADHAe8SoflayiXPjGRWTKaTULH5To_D_daVdoxMlD-jMOfF5AtTD1n9a-z0A1wwIXY-3OPfVpxtJ-fBx7WaGE6niUHtBQ9T4eTcZ3m_UFQL8T-FV8w_NQ
linkProvider	Wiley-Blackwell
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bT9swFD6CMjReYAMGZTA8CU3iIbSJ7SR9ZIWKS6mmqkh9s-JcRCVIUS-T-Pf7HKeZGBITEo9xbMc6N3_HPjmH6EjKkCdJSzi6mWSOEDpyosSPnCZPo1Br-HKBLTYR9HrhcNj6tUTtxb8wNj9EdeBmNKOw10bBzYF042_W0KvuzxN50zcVwMFr2V-mFeHzIKzRylm_c9utDDIQStNm43RNHECzvK3ELI1_53i-O72AnM8RbLEFdTbeZfGfaL1EoOzUisxnWkrzTdo6zeF9PzyxH6yICS0O2zdp1ZaqfNqi88H8YTxho_xupIsoL4anWdH2aCP6gNsZhI4lc3MlDnDPxhlrD9t9jlEsNtI12aZB53zQvnDKEgxOLADlnMzN_MSTXGvgNC0l92NAgjBzvQisDwUsJawph08FSxC7kYY6e6kIkgywg7v8C9XycZ7uEjPAxZfgfgaXFFO0_EAHOnaxSQMhRaJOjQXlVVymJzdVMu6VTazsKZBMlSRThmR1Oq5GPNrUHK_03V8wU5VKOlXAkmEAeBzyOn2vXkO9zJ1JlKfj-VR5gpsMPdxv1WnHCkH1MQ6PXkK4sPSC1_9dhWmACy7l3ptHHNLHi8FNV3Uve9dfac0zXn8RhrhPtdlknh7Qh_j3bDSdfCul_w-ll__c
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1bT9swFD5iZUO8AIMBZbB50jRpD6FNbOfyyArV2LoKVZ3UNyvORatE06qXSfz7fY7TTAyJCYnHOLZjnZu_Y5-cQ_RRypCnaSQc3U5zRwgdO3Hqx06bZ3GoNXy5wBabCPr9cDSKbjaos_4XxuaHqA_cjGaU9tooeDZL89bfrKHfel_O5Y-BqQAOXsvBC9oUMpKiQZuXg-7PXm2QgVDaNhuna-IA2tVtJWZp_TvH_d3pAeS8j2DLLai7-yyL36OdCoGyCysyr2kjK_bp4KKA9z25Y59YGRNaHrbv0ytbqvLugK6Gq8l0zsbFr7Euo7wYnpZl28xG9AG3MwgdS1fmShzgnk1z1hl1BhyjWGKka_6Ght2rYeerU5VgcBIBKOfkbu6nnuRaA6dpKbmfABKEuevFYH0oYClhTTl8KliCxI011NnLRJDmgB3c5YfUKKZFdkzMABdfgvs5XFJMEfmBDnTiYpMGQopFk1pryqukSk9uqmTcKptY2VMgmapIpgzJmvS5HjGzqTke6Xu6ZqaqlHShgCXDAPA45E36UL-Gepk7k7jIpquF8gQ3GXq4HzXpyApB_TEOj15CuLD0ktf_XYVpgAsu5cmTR7ynrZvLrupd97-_pW3POP1lFOIpNZbzVXZGL5Pfy_Fi_q4S_j8ti_9X
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tumor+inhibition+or+tumor+promotion%3F+The+duplicity+of+CXCR3+in+cancer&rft.jtitle=Journal+of+leukocyte+biology&rft.au=Russo%2C+Eleonora&rft.au=Santoni%2C+Angela&rft.au=Bernardini%2C+Giovanni&rft.date=2020-08-01&rft.issn=0741-5400&rft.eissn=1938-3673&rft.volume=108&rft.issue=2&rft.spage=673&rft.epage=685&rft_id=info:doi/10.1002%2FJLB.5MR0320-205R&rft.externalDBID=10.1002%252FJLB.5MR0320-205R&rft.externalDocID=JLB10655
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0741-5400&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0741-5400&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0741-5400&client=summon